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Abstract 
Epstein-Barr virus (EBV) is a tumor virus that establishes lifelong infection in most of 
humanity, despite eliciting strong and stable virus-specific immune responses. EBV 
encodes at least 44 miRNAs, most of them with unknown function. Here we show that 
multiple EBV’s miRNAs modulate immune recognition of recently infected primary B 
cells, EBV's natural target cells. EBV’s miRNAs collectively and specifically suppress 
release of pro-inflammatory cytokines such as IL-12, repress differentiation of naive 
CD4+ T cells to Th1 cells, interfere with peptide processing and presentation on HLA 
class II, and thus reduce activation of cytotoxic EBV- specific CD4+ effector T cells 
and killing of infected B cells. Our findings identify a previously unknown viral 
strategy of immune evasion. By rapidly expressing multiple miRNAs, which are 
themselves non-immunogenic, EBV counteracts recognition by CD4+ T cells and 
establishes a program of reduced immunogenicity in recently infected B cells allowing 
the virus to express viral proteins required for establishment of lifelong infection.  
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Abstract 
Infection with Epstein-Barr virus (EBV) affects most humans worldwide and persists 
lifelong in the presence of robust virus-specific T cell responses. In both 
immunocompromised and some immunocompetent people EBV causes several cancers 
and lymphoproliferative diseases. EBV transforms B cells in vitro and encodes at least 
44 miRNAs, most of which are expressed in EBV-transformed B cells, but their 
functions are largely unknown. Recently, we showed that EBV’s miRNAs inhibit CD4+ 
T cell responses to infected B cells by targeting IL-12, MHC class II, and lysosomal 
proteases. Here we investigated whether EBV’s miRNAs also counteract surveillance 
by CD8+ T cells. We have found that EBV’s miRNAs strongly inhibit recognition and 
killing of infected B cells by EBV-specific CD8+ T cells through multiple mechanisms. 
EBV’s miRNAs directly target the peptide transporter subunit TAP2 and reduce levels 
of TAP1, MHC class I molecules, and EBNA1, a protein expressed in most forms of 
EBV latency and a target of EBV-specific CD8+ T cells. Moreover, miRNA-mediated 
downregulation of IL-12 decreases the recognition of infected cells by EBV-specific 
CD8+ T cells. Thus, EBV’s miRNAs employ multiple, distinct pathways allowing the 
virus to evade surveillance not only by CD4+ but also by antiviral CD8+ T cells.   
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SUMMARY  
 
Epstein-Barr virus (EBV) is a herpesvirus that infects the majority (>90%) of the 
human population worldwide. EBV establishes a stable relationship with its host for a 
lifetime, which is mostly asymptomatic and under efficient control of the host’s T cells. 
As a consequence, in immunocompromised individuals, severe EBV-associated 
malignancies can develop. In order to prevent these diseases and find possible new 
therapeutic approaches, it is essential to study the mechanisms of viral immune evasion, 
which protect the virus-infected cells from eradication. 
To date, 25 microRNA (miRNAs) precursors have been identified in EBV's genome 
and accumulating evidences suggest that they might subvert the host’s antiviral immune 
response. We used deep-sequencing techniques to analyze the contribution of EBV’s 
miRNAs in primary B cells infected with EBV for five days. We found cellular 
transcripts related to adaptive and innate immunity among the most affected pathways 
in the presence of EBV’s miRNAs. 
The combination of RNA-seq and RISC-IP-seq analyses revealed that IL12B was 
the top downregulated gene, but pro-inflammatory cytokines such as IL-6 and TNF-α 
appeared to be controlled as well. Interestingly, we could validate IL12B as the direct 
target of five different viral miRNAs. We found that reduced level of IL-12 secreted 
from EBV-infected B cells reduced differentiation of antiviral Th1 cells.  
We could also validate the miRNA-mediated reduction of TAP1 and TAP2, two 
proteins that form the heterodimeric transporter of processed peptides from the 
cytoplasm to the ER lumen. Furthermore, we observed that MHC class I, all three 
subclasses of MHC class II molecules (HLA-DR, HLA-DQ and HLA-DP), and several 
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costimulatory and adhesion molecules were downregulated in the presence of EBV’s 
miRNAs.  
The activation of EBV-specific CD4+ T cells was reduced in co-culture experiments 
with B cells infected with EBV strains expressing viral miRNAs in contrast to B cells 
infected with a strain incapable of expressing them. Similarly, we found that the 
recognition and killing of EBV-infected B cells by EBV-specific CD8+ T cells was 
strongly reduced by EBV’s miRNAs.  
In addition, other direct targets of viral miRNAs were identified, including viral 
proteins such as LMP1 and three important lysosomal enzymes, which further 
contribute to the immune evasive phenotype that we identified. 
Overall, our findings provide the first evidence that EBV’s miRNAs have an 
important role in adaptive immune evasion of EBV-infected cells. The viral miRNAs 
repress several genes involved in different steps of cellular immune recognition.  
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INTRODUCTION 
1. Epstein-Barr Virus 
Epstein-Barr Virus (EBV), also known as human herpes virus 4 (HHV-4), belongs 
to the family of gamma herpes viruses. EBV is an enveloped virus of approximately 
180 nm in size with a double-stranded DNA genome of 160 kb that encodes about 85 
open reading frames (ORFs). More than 90% of the worldwide population is infected 
with the virus, in which the virus persists lifelong, often asymptomatically (IARC 
Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010). However, 
when the first viral infection does not take place early during childhood but occurs later 
during adolescence or in adults, EBV can cause acute infectious mononucleosis (IM), 
which is characterized by high fever, enlarged lymph nodes, and tiredness (Rickinson 
et al., 2014). These patients have a higher risk of developing malignant diseases 
(Crawford, 2001) and multiple sclerosis (MS) later in their lives (Achiron, 2004).   
EBV predominantly infects B cells, mainly resting B cells, in which the virus 
establishes a latent infection. During latency, only a limited number of viral genes is 
expressed, preventing the recognition of the infected B cells by the immune system. 
Indeed, the EBV infection is never completely cleared by the host immunity (Chen, 
2011). 
Several malignancies are linked to EBV, such as Hodgkin Lymphoma (HL), 
Burkitt’s lymphoma (BL), and post-transplant lymphoproliferative disorder (PTLD). 
PTLD occurs in immunocompromised individuals, who have a reduced immune 
surveillance of EBV-infected B cells (Gottschalk et al., 2005), indicating that the virus 
causes this disease. EBV-associated diseases other than PTLD, likely emerge from co-
morbidities or co-factors, which are mostly unknown. 
 
Epstein-Barr Virus   INTRODUCTION 
 11 
1.1  EBV’s replication cycle 
Infection of EBV initiates via the envelope glycoprotein 350 (gp350) that binds to 
the cellular complement receptor 2 (CR2 or CD21) (Nemerow et al., 1987; Wang and 
Hutt-Fletcher, 1998), which is present on B cells but also on certain epithelial cells. 
Infection of B cells in vitro induces their activation, proliferation and immortalization 
leading to the generation of lymphoblastoid cell lines (LCLs). LCLs are a useful model 
to study and characterize many steps of the viral replication cycle and its impact on 
infected cells.   
The viral glycoprotein 42 (gp42) contributes to the interaction between virions and 
target cells binding to the major histocompatibility complex II (MHC-II). Differently 
from B cells, epithelial cells lack MHC-II, therefore in vitro infection of these cells is 
very inefficient (Wang et al., 1998; Shannon-Lowe et al., 2009). 
Immediately after B cell infection, several latent and many early-lytic viral genes 
are expressed. The latter are only transiently expressed early after infection to support 
survival and cell cycle entry of resting B cells, but not expressed later when latency is 
established (Kalla and Hammerschmidt, 2012).  
Among these lytic genes, two viral homologous of cellular anti-apoptotic BCL-2 
proteins,  BHRF1 and BALF1, are essential for initial cell transformation (Altmann and 
Hammerschmidt, 2005).  
During the early phase of infection, named EBV’s transitional pre-latent phase, the 
EBV nuclear antigen 2 (EBNA2) is the earliest latent protein detected (Allday et al., 
1989), which is essential for the cellular transformation. EBNA2 acts as transactivator 
of other viral genes, such as the latent membrane protein 1 (LMP1) and 2 (LMP2) and 
many other cellular genes (Fields et al., 2007; Zimber-Strobl and Strobl, 2001).  
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The EBV nuclear antigen 1 (EBNA1) is also expressed early after infection and has 
many key functions for the virus. During the early phase, EBNA1 is essential for the 
expression of EBV’s transforming latent genes (Altmann et al., 2006), because it acts 
as a transcription factor on promoters of certain viral latent genes (Kennedy and 
Sugden, 2003). When the cells start dividing four days post-infection, EBNA1 is 
necessary for the replication, segregation and maintenance of the viral genome in the 
infected cells (Yates et al., 1985; Levitskaya et al., 1997). 
During the pre-latent phase, the latent membrane proteins LMP1 and LMP2 
promote the activation and proliferation of infected B cells. LMP1 mimics a 
constitutively active CD40 receptor and therefore does not depend on CD40 ligand 
(CD40L) to be active (Gires et al., 1997; Kutz et al., 2008). Expression of LMP1 is 
important for B cell-transformation, inducing an activated phenotype (Dirmeier et al., 
2003). LMP2 mimics the B-cell receptor (BCR) providing an effective survival signal 
for infected B cells (Mancao and Hammerschmidt, 2007; Merchant et al., 2001). 
Seven to ten days after infection, the virus expresses only eight latent proteins: six 
EBV nuclear antigens (EBNA1, 2, 3A/B/C and LP) and the membrane proteins (LMP1 
and 2). During this phase of latent infection, called “Latency III” or growth program, 
the cells are fully activated and proliferate, giving rise to lymphoblastoid cell lines 
(LCLs) (Scheme 1). LCLs established after in vitro infection of B cells express the set 
of genes characteristic of the latency III “growth program”. However, because of an 
efficient control of the immune system in vivo, infected B cells further reduce the 
expression of viral genes, limiting their immunogenicity. The different types of viral 
latencies are classified depending on the number of proteins expressed: latency II (four 
proteins), latency I (EBNA1 only) and latency 0 or “true latency” in which no viral 
proteins are expressed (Babcock and Thorley-Lawson, 2000). Infected B cells in 
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latency 0 are considered to be peripheral resting B cells that recirculate between the 
blood and the oropharyngeal lymphoid tissues (Taylor et al., 2015) (Scheme 1). 
Latently infected memory B cells sporadically reactivate entering the lytic cycle, 
probably induced by their differentiation to plasma cells or by other signals from the 
extracellular environment. Activated memory B cells produce progeny virions, which 
spread to other B cells allowing the virus to survive in its host lifelong. The different 
types of viral latencies are also observed in many EBV associated diseases: post-
transplant lymphoproliferative disease (PTLD; type III), Hodgkin’s disease (type II), 
gastric carcinoma, nasopharyngeal carcinoma (type I/II) and Burkitt’s lymphoma (type 
I) (Rickinson et al., 2014) (Scheme 1). 
In addition, EBV expresses different non-coding RNAs, such as Epstein-Barr virus-
encoded RNAs (EBER), the BamHI-A rightward transcripts (BARTs), the small 
nucleolar RNAs (snoRNA1) and EBV’s miRNAs (described below). The specific 
functions of most viral non-coding RNA remain still controversial and unclear, but the 
EBERs are used as biomarker in clinical practice since they are highly abundant and 
expressed in all the EBV-infected cells in vivo (Skalsky and Cullen, 2015). 
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Scheme 1.  EBV’s replication cycle 
A. Within the first phase post infection, called pre-latent phase, few viral genes are expressed aiming to 
immortalize the infected cells and establish its latency. Sporadic lytic reactivation is observed, the 
production of new virions allows the virus to spread into other target cells and to infect the host lifelong. 
B. Description of the EBV viral latencies. The latency programs differ according to the gene expression 
pattern of the infected cells; each type has a different cellular phenotype and is associated with distinct 
malignancies. dpi = days post infection. 
 
 
2. Adaptive immune response against EBV 
During primary infection, the virus is rapidly detected by components of the innate 
immune system, which initiate a direct antiviral response and prime the adaptive 
immunity. 
Immune responses are crucial to control the virus both in acute and chronic 
infections. Adaptive immune responses can be divided into the humoral response, 
which is antibody mediated, and the cell-mediated response.  
 
A
B
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2.1  Antibody responses  
The humoral response is mediated by plasma B cells, which release antibodies, a 
soluble form of the BCR with specificity to recognize various types of antigens. 
Acute IM patients show a strong production of IgM antibodies specific for the viral 
capsid antigen (VCA) as an early response against the virus. IgM antibody levels 
decrease after a few days and are replaced by a class of IgG antibodies directed against 
VCA, the EBV early antigen (EA-D) and EBNA2 (Taylor et al., 2015). After the acute 
phase of infection, these antigens rapidly decline and a peak of IgG response against 
EBNA1 can be detected from three-six months after infection. The IgG response 
reaches a stable level and persists for life. In seropositive individuals, IgG antibodies 
against EBNA1 can be always detected, while newly produced IgM antibodies, mainly 
directed against VCA, are detected only upon viral reactivation (Klutts et al., 2004).  
 
2.2  T cells responses  
The cell-mediated response is mediated by the interaction of the Major 
Histocompatibility complex also known as the human leukocyte antigen (HLA), 
expressed on target cells and the T cell receptor (TCR), on T cells.  
MHC class I molecules are expressed on any nucleated cell and present short 
antigenic peptides to CD8+ T cells. MHC-II molecules, primarily expressed on antigen 
presenting cells (APC), present peptides of phagocyted proteins to CD4+ T cells. B cells 
are considered to be APC because they express both MHC-I and MHC–II molecules, 
therefore infected B cells are potentially recognized by both CD4+ and CD8+ T cells. 
The CD8+ T cells are known to be the effector T cells responsible for the clearance of 
the infected cells and CD4+ T cells are considered to have a role in supporting and 
shaping the immune response to the pathogen. 
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During acute infection, EBV-infected cells are more susceptible to T cells 
recognition compared to latently infected cells. IM patients show a dramatic expansion 
of global CD8+ T cells with high frequencies of EBV-specific CD8+ T cells, up to 50% 
of which recognize lytic antigens (Hislop et al., 2007). Although the numbers of CD4+ 
T cells do not increase as much as CD8+ T cells, activated EBV-specific CD4+ T cells 
represent up to 1% of the peripheral CD4+ T cells (Long et al., 2013). It has been 
reported that EBV-specific CD4+ T cells against lytic antigen show a strong cytotoxic 
phenotype (Adhikary et al., 2006; Münz et al., 2000; Long et al., 2005). 
When the acute infection comes to an end, the levels of EBV-specific T cells 
decrease with the reduction of circulating virus. In healthy, EBV-positive individuals 
EBV-specific CD4+ T cells constitute less than 0.1% of the total CD4+ T cell population, 
but EBV-specific CD8+ T cells may still represent up to 2% of all peripheral CD8+ T 
cells. Furthermore, T cells specific for peptides derived from lytic antigens are twice as 
many compare with CD8+ T cells that recognize epitopes of latent antigens (Abbott et 
al., 2013). In case of lytic reactivation, the adaptive immunity relies on a strong memory 
response of these EBV-specific T cells. 
During latency, EBV-infected B cells are almost invisible to virus-specific T cells 
because the virus dramatically reduces the expression of viral proteins to limit the 
amount of antigen. This situation accounts for the asymptomatic infection of EBV in 
the majority of the population. In individuals with an impaired T cell immunity, EBV 
can promote the development of malignances such as post-transplant 
lymphoproliferative disease (PTLD) and Hodgkin’s disease, underlining the important 
role of T cells, which keep the virus under control.  
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3. EBV immune evasion 
The ability of EBV to establish a latent infection and to infect its host lifelong, 
despite a strong immunity against the virus, suggests that EBV has developed very 
efficient strategies to evade the immune system. 
During lytic reactivation, EBV expresses more than 80 viral genes. Their products 
make the virus-infected cells more susceptible to immune surveillance. Among these 
proteins, more than eight are reported to act as immunoevasins (Ressing et al., 2015), 
limiting the activation of the immune system that would otherwise eliminate the virus-
producing cells, thereby preventing the release of progeny viruses and viral spread to 
other target cells.  
EBV’s immunoevasins inhibit several steps of MHC class I and II mediated epitope 
presentation, some of which are shared with other herpesviruses. BGLF5 is a protein 
with DNase and RNAse activities that promotes mRNA degradation and reduces the 
levels of the MHC-I gene transcripts (Zuo et al., 2009). BILF1 is a G-protein coupled 
receptor that localizes to the plasma membrane. BILF1 can directly interact with MHC 
class I promoting its lysosomal degradation and reducing its surface levels (Paulsen et 
al., 2005). Interestingly, HLA-A and B but not HLA-C are affected (Griffin et al., 
2013), probably preventing the recognition of the virus producing cells by natural killer 
(NK) cells. NK cells are particularly sensitive to abnormal HLA-C levels, since the 
reduction of these molecules leads to NK cells activation (Blais et al., 2011).  
Other two important EBV immunoevasins are BNLF2a and the EBV homologue of 
IL-10, v-IL-10 (also named BCRF1). These two viral proteins inhibit the transporter 
associated with antigen processing (TAP) through different mechanisms; BNLF2a 
binds to the cytosolic domains of TAP and blocks both peptide and ATP binding (Horst 
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et al., 2011; Wycisk et al., 2011), while v-IL-10 decreases the mRNA and protein levels 
of TAP1 (Zeidler et al., 1997). 
The TAP complex is a heteroduplex formed by TAP1 and TAP2 and necessary for 
the translocation of peptides generated by the proteasome from the cytosol to the 
endoplasmic reticulum (ER). The peptides transported into the ER are then loaded onto 
MHC-I molecules and presented on the cell surface to CD8+ T cells. The unique role of 
the TAP complex in MHC-I presentation makes TAP an appropriate target for viral 
strategies of immune evasion. In fact, not only EBV but also many other viruses 
actively reduce TAP activity: US6 encoded by human cytomegalovirus (HCMV) (Ahn 
et al., 1997; Hengel et al., 1997; Lehner et al., 1997), CPXV012 of several cowpox 
virus strains (Alzhanova et al., 2009; Byun et al., 2009), ICP47 encoded by herpes 
simplex virus (HSV)-1 and HSV-2 (Hill et al., 1995; Ahn et al., 1996; Tomazin et al., 
1996), UL49.5 encoded by varicella virus, as well as bovine herpes virus (BHV)-1, 
BHV-5 and equine herpes virus (EHV)-1 and EHV-5 (Koppers-Lalic et al., 2008). 
EBNA1 is the only EBV protein that is expressed in almost all types of viral 
latencies. As such, it is important for EBNA1 to reduce its own presentation via MHC-
I limiting the recognition of EBV-infected cells by EBNA1-specific CD8+ T cells. 
EBNA1 contains a repetitive amino acid sequence of glycin-alanine (GAr) that inhibit 
translation of EBNA1 itself and interferes with its proteasome degradation and peptide 
presentation via MHC-I (Levitskaya et al., 1995, 1997; Yin et al., 2003). Despite these 
EBNA1-specific immune evasive mechanisms, EBNA1-specific CD8+ as well as CD4+ 
T cells are prevalent in the majority of EBV-positive individuals and are probably 
important to keep the virus under control. 
In contrast to the well described strategies of EBV immune evasion during lytic 
reactivation, it is not clear how the infected B cells can evade T cell recognition 
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immediately after infection, for example during the pre-latent phase, or during latency 
III. In these phases the infected B cells show an activated phenotype that support an 
efficient antigen presentation. During latency III, more than eight EBV proteins are 
expressed. Similarly, in the pre-latent phase, dozens of viral proteins are expressed and 
functionally presented. Thus, these fully activated B cells need to reduce their 
recognition by EBV-specific T cells. It was shown that BNLF2a and v-IL-10, known 
to act during the lytic phase, are also expressed and active during the pre-latent phase 
(Jochum et al., 2012a). The BNLF2a protein inhibits CD8+ T cells recognition by 
downregulating the TAP complex and the viral IL-10 reduces cytokines important for 
anti-viral CD4+ T cell activity. 
During latency III, EBNA1, LMP1, and LMP2 are proteins with described immune 
evasive functions. LMP1, similar to EBNA1 reduces the presentation of its own 
peptides in cis (Smith et al., 2009). LMP2 was reported to downregulate the activation 
of CD8+ T cells by reducing ligands of the Natural Killer Group 2D (NKG2D) receptor 
(Rancan et al., 2015). Despite these known immunoevasive functions, B cells infected 
with EBV mutants that do not express these immunoevasins are still recognized by T 
cells in pre-latent phase and in latency III (Rancan et al., 2015; Jochum et al., 2012a). 
It is likely that other viral immunoevasins, which have not been identified so far, are 
responsible to protect the infected cells from immune surveillance to establish and 
maintain a persistent infection in vivo. EBV’s miRNAs seem to be the perfect 
immunoevasins candidates: they are expressed in all known phases of EBV (Cai et al., 
2006; Seto et al., 2010), they are not immunogenic, since they are non-coding RNA and 
they are indistinguishable from miRNAs of the host cells. In addition, miRNA are 
present in EBV virions and passively transferred to newly infected B cells (Jochum et 
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al., 2012b), indicating that they can be functional even prior to de novo transcription 
from the incoming viral genome. 
In fact, there are few reports describing viral miRNAs as immunoevasins. Two 
reports come from analyzing human cytomegalovirus (HCMV): Stern-Ginossar et. al. 
showed that miR-UL112 targets and reduces the expression of MICA, a stress induced 
immune ligand (Stern-Ginossar et al., 2008); Kim et al. showed that the viral miRNA 
miR-US4-1 reduces the recognition of CD8+ T cells by directly targeting the 
endoplasmic reticulum aminopeptidase 1 (ERAP1) (Kim et al., 2011). ERAP1 is an 
important protein that trims the peptides in the ER optimizing the stable binding 
between peptides and MHC-I molecules (Saric et al., 2002). Another report of viral 
miRNAs acting as immunoevasins comes from simian virus (SV40): it was shown that 
SV40 encoded miRNAs downregulate the viral T antigen, thus reducing antigen levels 
and the activation of T cells specifically directed against this viral protein (Sullivan et 
al., 2005). 
 
4. EBV’s microRNAs  
microRNAs (miRNAs, miRs) are small, single-stranded RNAs of about 21 to 24 nt 
in length that cause translational inhibition or deadenylation followed by the 
degradation of the targeted mRNA transcripts. The miRNA’s region that binds the 
mRNA target is called the “seed sequence” and consists of six nucleotides located at 
the 5’ end (from nucletotide 2 to 8) of the miRNA molecule(Bartel, 2004). The miRNA 
binds to the targets mainly within their 3’-untranslated regions (3’-UTRs) and by 
Watson-Crick partially bulged complementary base pairing. Therefore, each miRNA 
species can have multiple targets and, in the same way, one mRNA can be targeted by 
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many miRNAs due to the only partial complementarity between miRNA and the 
mRNA target (Ambros, 2004; Bartel, 2004). 
EBV encodes 44 different mature miRNAs (Cai et al., 2006; Pfeffer et al., 2004), 
divided into three clusters: BHRF1 cluster, BART cluster 1 and 2. The EBV genome 
of the laboratory strain B95.8 (NC-007605.1) has a deletion of about 11.8 kb (Skare et 
al., 1982), which contains the majority of BART miRNA cluster. Interestingly, this 
strain can still infect and immortalized B cells both in vitro and in vivo (Miller et al., 
1972), indicating that the missing miRNAs in this EBV strain are not essential to 
establish latent infections in B cells. 
Our comprehension of EBV’s miRNAs and their functions is still limited. Certain 
viral miRNAs clearly play a role in B cell “transformation” by EBV. Experiments 
performed by our group and others using viruses devoid of all or certain miRNAs 
underline the role of miRNAs of the BHRF1 cluster in cell cycle progression and B 
cells immortalization (Seto et al., 2010; Vereide et al., 2013; Feederle et al., 2011b). 
EBV mutants with a knockout (KO) of this cluster can still immortalize B cells and 
establish a latent infection in vivo, but with a delayed kinetics (Wahl et al., 2013).  
Several groups used high-throughput approaches based on a combination of 
immunoprecipitation of the RNA-induced silencing complex (RISC-IP), the complex 
that mediates the interaction between miRNA and target, and RNA-sequencing to 
discover new targets. These approaches generated long lists of putative targets, which 
mostly have not been functionally validated (Riley et al., 2012; Skalsky et al., 2012; 
Vereide et al., 2013). Surprisingly, the published lists of predicted targets show only 
very small overlaps (Klinke et al., 2014), which might be due to different long-term 
cultivated cell lines used by the different groups. 
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To date, few targets of EBV’s miRNAs have been confirmed. Many of the identified 
targets encode pro-apoptotic proteins such as BBC3, BCL2L11 or CASP3 (Choy et al., 
2008; Vereide et al., 2013; Marquitz et al., 2011). Only a small number of targets are 
involved in innate immunity and inflammation. The EBV-miR-BART13-5p was shown 
to target the mRNA of NLRP3 and repress the inflammasome’s activation and the 
subsequent release of the pro-inflammatory cytokine interleukine 1β (IL-1 β) 
(Haneklaus et al., 2012). 
The IFN-inducible T-cell attracting chemokine CXCL11 has been reported to be a 
target of EBV miR-BHRF1-3 (Xia et al., 2008). These authors suggested that this 
suppression might serve as an immunomodulatory mechanism in EBV-associated 
lymphomas.  
MICB is targeted by EBV miR-BART2-5p and its downregulation allows the 
infected B cells to escape recognition and elimination by NK cells (Nachmani et al., 
2009). Interestingly, the same group found that the 3’UTR of MICB is also a target of 
miRNAs of other herpesviruses (KHSV and HCMV), suggesting that the reduction of 
this NK ligand is important for viral immune escape. 
Interestingly, EBV’s miRNAs are also reported to target several viral mRNAs 
including LMP1 (Lo et al., 2007), BZLF1 (Jung et al., 2014) and LMP2 (Lung et al., 
2009) most likely to reduce the antigenicity caused by the expression of these viral 
proteins. 
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4.1  EBV’s miRNAs support cell proliferation and prevent 
apoptosis 
EBV encodes the largest number known among human herpesviruses (Kincaid et 
al., 2012). To date, the role of the majority of EBV’s miRNAs is not well characterized.  
We and others reported that one of the important functions of EBV’s miRNAs early 
after infection is to support survival of infected B cells by promoting cell cycle, 
proliferation and suppressing apoptosis (Feederle et al., 2011b; a; Vereide et al., 2013; 
Seto et al., 2010). This feature of viral miRNAs is now better characterized and many 
viral miRNAs’ targets involved in these pathways have been found, such as the pro-
apoptotic genes BBC3 (PUMA) (Choy et al., 2008), BAX (Strasser, 2005), CASP3 
(Vereide et al., 2013), and BCL2L11 (BIM) (Marquitz et al., 2011). The virus has 
therefore a better chance to reach its latent phase and to establish its lifelong infection. 
In these studies, isolated B cells have been used and the effects of miRNAs appear to 
be beneficial but not essential for the infected B cells to survive. Since EBV is orally 
transmitted via saliva, primary infection targets submucosal B cells are surrounded by 
a variety of other cell types, including immune cells. Furthermore, when the virus enters 
lytic reactivation and progeny virions are produced, the infected B cells are probably in 
a highly immune competent micro-environment (Laichalk and Thorley-Lawson, 2005; 
Tugizov et al., 2003).  
For these reasons, we established a model of infection that closely resembles the in 
vivo situation. Isolated peripheral blood mononuclear cell (PBMC) were infected with 
two EBV strains that differ in their capacity to encode viral miRNAs. After 6 weeks, 
MTT assays were performed to assess the viability of the cells (Fig 1A). Interestingly, 
B cells infected with the wt/B95.8 virus that encodes viral miRNAs grew out in up to 
30 out of 30 wells, while surviving B cells infected with the ΔmiR strain of EBV were 
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only found in at most five wells of 30 wells indicating a very strong impact of viral 
miRNAs on the survival of B cells in this complex model with PBMCs (Fig. 1A). Since 
we miss the non-infected control, we cannot exclude that the B cells that outgrew in the 
PBMCs infected with ΔmiR are a consequence of the reactivation of the field strain 
virus, since the donors used for the experiment were all EBV positive. 
The contribution of the viral miRNAs to B-cell survival is much stronger than the 
one observed before with isolated B cells (Vereide et al., 2013; Seto et al., 2010; 
Feederle et al., 2011b; a), suggesting that miRNAs are also involved in mechanisms 
other than pure regulation of pro-apoptotic cellular functions. Our experiment 
suggested that miRNAs could reduce cell-cell communication with immune cells 
thereby increasing the chance of EBV to establish a latent infection.   
EBV’s microRNAs   INTRODUCTION 
 25 
 
 
 
 
Fig. 1. EBV’s miRNAs are important to establish a viral latent infection 
A. PBMCs were isolated by Ficoll gradient centrifugation from three EBV-positive donors and infected 
with wt/B95.8 or ΔmiR EBV strains at an MOI 0.1. The medium of the infected cells was refreshed 
weekly and a MTT assay was performed. To assess the viability of the cells after 6 weeks. The 
experiment was performed in 30 replicates. A strong purple color indicates cellular proliferation of EBV-
infected cells. B. CD19+ B cells were isolated from PBMCs by positive selection using CD19+ beads. 
Isolated B cells were infected with wt/B95.8 or ΔmiR EBVs at an MOI 0.1 and seeded in a 96 wells plate 
in different conditions (from 500 to 64,000 cells/well). The medium was refreshed weekly. Four weeks 
after infection the viability of the cells was addressed by MTT assay (OD 595nm). The experiment was 
performed in 6 replicates. C. CD19+B cells and CD8+ T cells were isolated from PBMCs of EBV-positive 
donors with magnetic beads coupled with appropriate antibodies. B cells were infected and seeded using 
32,000 cells/well. At this condition, no difference in proliferation was observed between the two viral 
strains (B). Isolated CD8+ T cells were added to the infected B cells at different B: T cells ratios. The 
medium was refreshed weekly. Four weeks after infection the viability of the cells was analyzed by MTT 
assay. Values (%) are normalized with respect to control B cells, only, set to 100%. The experiment was 
performed in 6 replicates. One donor out of 3 is shown as a representative experiment. 
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4.2  EBV’s miRNAs prevent the recognition by antiviral T cells 
EBV-infected B cells are constantly under immune surveillance in vivo. Among the 
immune cells, cytotoxic CD8+ T cells (CTL) are mainly responsible for the killing of 
latently infected cells. To analyze if EBV’s miRNAs affect the CTL immune 
surveillance, we developed a simple but effective model (Publication 2 Fig. 1). Isolated 
B cells from EBV-positive donors were infected with wt/B95.8 or ΔmiR viruses and 
seeded under different conditions (Fig. 1B). As expected, B cells infected with the 
wt/B95.8 strain proliferated under all conditions, while B cell infected with ΔmiR EBV 
showed a strongly reduced outgrowth.  
To address the effects of EBV’s miRNAs on CTL immune surveillance, we used 
purified B cells infected with the two EBV viruses (wt/B95.8 or ΔmiR) and seeded at 
32,000 cells/well. At this initial cell density, all wells contained proliferating B cells 
four weeks after infection, irrespective of the EBV strain used (Fig. 1B). The initially 
seeded cells were co-cultured with isolated CD8+ T cells from the same donor using 
different B to T cells ratios (Fig. 1C). In the presence of T cells and already at low T 
cells ratios the outgrowth of B cells infected with the virus devoid of miRNAs (ΔmiR) 
was dramatically decreased. Similarly, about four times more T cells were required to 
affect the outgrowth of wt/B95.8-infected B cells. These data indicate that EBV’s 
miRNAs can prevent, directly or indirectly, the eradication of EBV-infected B cells by 
CTL. This finding can also explain why in PBMCs from EBV-positive donors only B 
cells infected with the EBV strain wt/B95.8 but not B cells infected with ΔmiR EBV 
grew out efficiently (Fig. 1A). 
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4.3  Why miRNAs? 
Many EBV immunoevasins have been described, but the ones identified so far are 
all viral proteins. As such, they are processed and presented in the infected B cells to 
both CD8+ and CD4+ T cells and their expression could be counterproductive for the 
virus by increasing the immunogenicity of the infected cells. The virus establishes 
latency by switching off the expression of as many proteins as possible to become 
almost “invisible” to the immune system rather than using additional viral proteins for 
immune evasion.  
EBV’s miRNAs are known to be expressed in all phases of EBV infection (Qiu et 
al., 2011), including all the known forms of viral latency. EBV’s miRNAs are 
potentially active even immediately after viral infection, since they have been identified 
to be contained in EBV virions (Jochum et al., 2012b). 
It is appealing to consider that EBV uses its miRNAs as immunoevasins to escape 
from host immune surveillance, since they cannot be “seen” by T cells and they do not 
trigger any pattern recognition receptors (PRR) that would activate innate immune 
responses against the virus. As such, miRNAs can be a perfect immune evasive tool for 
viruses such as EBV. 
With this working hypothesis at hand and our preliminary experiments shown in 
Fig. 1, we decided to study the role of EBV’s miRNAs in immune evasion to understand 
what their molecular functions are (Tagawa et al., 2016; Albanese et al., 2016).  
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AIM OF THE THESIS 
The aim of this study was to investigate the role of EBV’s miRNAs in immune 
evasion. We sought to achieve a better understanding of how they contribute to hiding 
the presence of the virus from the host’s immunity and to establish and maintain a 
lifelong infection. Our approach followed two main lines: 
 
I) Identification and validation of new EBV’s miRNAs targets 
Isolated B cells can be easily infected with EBV in vitro, leading to the generation 
of immortalized LCLs. We used two viruses based on the B95.8 EBV genome 
previously established in our lab (Delecluse et al., 1998) called wt/B95.8 EBV here. 
This virus expresses only 13 out of 44 miRNAs, because it has a deletion of 
approximately 11.8 kb which includes the majority of the BART cluster encoding many 
viral miRNAs.  
In this study, we compared B cells infected with wt/B95.8 EBV with B cells infected 
with a mutant virus devoid of all miRNAs (ΔmiR), which was also established in our 
lab (Seto et al., 2010). Because we are interested in the first initial phase of infection, 
the so-called pre-latent phase, we characterized newly infected B cells to avoid a 
possible bias introduced by long-term culture of lymphoblastoid cell lines.  
We used a combination of different next generation sequencing techniques to 
identify putative direct targets of EBV’s miRNAs. Ideally, a perfect target should be 
differentially expressed in RNA-seq analysis, indicating that the expression of the 
transcript is reduced in the presence of EBV’s miRNAs. The ideal target should also be 
enriched in RISC-IP-Seq, indicating that one or more EBV’s miRNAs directly interact 
with the target mRNA, usually within its 3’UTR. We then used bioinformatics tools 
(e.g. RNAhybrid or Targetscan) to determine which viral miRNA is predicted to 
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regulate a certain target. If a target fulfilled all these criteria, we introduced its 3´UTR 
into a dual-luciferase reporter plasmid and tested it together with the predicted single 
or multiple miRNAs. Finally, the reduced expression of the target had to be confirmed 
using quantitative PCR (qPCR) of its mRNA and western blot (WB) detection of its 
protein level.  
 
II) Interference of EBV’s miRNAs with immune cells functions  
To address whether EBV’s miRNAs interfere with adaptive immune responses, we 
established different polyclonal or monoclonal EBV-specific T cells. 
Monoclonal EBV-specific T cell can be rapidly established by stimulating T cells 
isolated from PBMCs of EBV-positive donors with autologous or HLA matched 
antigen presenting cells (APCs) loaded with specific peptides (Bollard et al., 2008; 
Moosmann et al., 2010). EBV-specific T cell clones can be used as tools to evaluate 
the presentation of a specific peptide using infected B cells as APC. The activation of 
the T cells depends on the ability of the APCs to present the specific peptide. Once 
activated, EBV-specific T cells release a proportional amount of IFN-γ that can be 
quantified by ELISA. 
Polyclonal EBV-specific T cells can be established by stimulating T cells (CD8+ or 
CD4+) isolated from PBMCs of EBV-positive donors with autologous LCLs, every 
second week. The peculiarity of these EBV-specific T cell lines is that they recognize 
a broad range of antigens from different viral proteins, providing a more diverse view 
of antigens presentated by autologous or HLA-matched target cells. 
B cells infected with wt/B95.8 or ΔmiR EBV strains were co-cultured together with 
EBV-specific T cells. This model can be used to evaluate the activities of these T cells 
as a function of the immunomodulatory impact of EBV’s miRNAs. This approach is 
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extremely sensitive and allows the identification of differences with respect to 
cytokines release and T cells mediated killing of antigen presenting cells. 
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INT ROD UCT ION
EBV is both ubiquitous and immunogenic. This oncogenic 
herpesvirus (IARC Working Group on the Evaluation of 
Carcinogenic Risks to Humans, 2010) has evolved multiple 
genes to fend off immune responses when its infection is es-
tablished (Hislop et al., 2002; Rowe et al., 2007; Ressing et 
al., 2008; Zuo et al., 2009; Qiu et al., 2011; Rancan et al., 
2015). Despite these measures, EBV-specific T cells consti-
tute a considerable fraction of the memory T cell repertoire 
of the latently infected human host (Hislop et al., 2002) and 
are essential in controlling latent EBV infection (Moos-
mann et al., 2010). In fact, immunocompromised patients 
have an increased incidence of EBV-associated malignancies 
(Gottschalk et al., 2005).
EBV infects nondividing B lymphocytes, activates them, 
and drives them to proliferate, thus amplifying the load of 
viral genomes. Once activated, infected B cells acquire prop-
erties of antigen-presenting cells. After infection, they rapidly 
present epitopes of structural proteins from incoming virus 
particles and transiently express lytic genes that are otherwise 
characteristic of EBV's productive cycle (Kalla and Ham-
merschmidt, 2012). This prelatent phase of infection includes 
expression of two genes coding for viral immunoevasins, 
BNLF2a and BCRF1 (Jochum et al., 2012), which inhibit 
the recognition of the infected cells by EBV-specific effector 
T cells and natural killer cells, respectively. These two viral 
proteins are insufficient, however, to overcome T cell recog-
nition (Jochum et al., 2012). Within 7–10 d, EBV establishes 
a latent infection in the infected B cells and expresses only 
few or no viral genes, which reduces their risk of becoming 
eliminated by the immune-competent host.
Thus, early infection could be EBV’s Achilles heel, a 
window when the infected cell expresses and presents many 
viral antigens to immune cells but is inadequately protected 
from the host's immune response. We have now established 
that EBV's miRNAs overcome this vulnerability; they protect 
newly infected B lymphocytes from immune eradication by 
CD4+ T cells, supporting EBV’s lifelong success.
EBV encodes at least 44 microRNAs (miRNAs; Barth et 
al., 2011), which are small RNA regulatory molecules of ∼22 
nt in length (Bartel, 2004). miRNAs encoded by herpesviruses 
Epstein-Barr virus (EBV) is a tumor virus that establishes lifelong infection in most of humanity, despite eliciting strong and 
stable virus-specific immune responses. EBV encodes at least 44 miRNAs, most of them with unknown function. Here, we show 
that multiple EBV miRNAs modulate immune recognition of recently infected primary B cells, EBV's natural target cells. EBV 
miRNAs collectively and specifically suppress release of proinflammatory cytokines such as IL-12, repress differentiation of 
naive CD4+ T cells to Th1 cells, interfere with peptide processing and presentation on HLA class II, and thus reduce activation 
of cytotoxic EBV-specific CD4+ effector T cells and killing of infected B cells. Our findings identify a previously unknown viral 
strategy of immune evasion. By rapidly expressing multiple miRNAs, which are themselves nonimmunogenic, EBV counteracts 
recognition by CD4+ T cells and establishes a program of reduced immunogenicity in recently infected B cells, allowing the virus 
to express viral proteins required for establishment of life-long infection.
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are reported to play important roles in cell proliferation, de-
velopment, immune regulation, and apoptosis in infected cells 
(Skalsky and Cullen, 2010). The EBV-encoded miRNAs have 
been found to control expression of several cellular genes with 
antiapoptotic functions, but they also reportedly down-regulate 
MICB (Nachmani et al., 2009), CXCL11 (Xia et al., 2008), and 
NLRP3 (Haneklaus et al., 2012) and thus interfere with innate 
immune responses and inflammation. Interestingly, MICB, a 
gene encoding a ligand for the activating receptor NKG2D 
expressed on T and NK cells, is also targeted by miRNAs of 
Kaposi sarcoma–associated herpesvirus and human cytomega-
lovirus (Nachmani et al., 2009; Grundhoff and Sullivan, 2011). 
These studies imply that certain miRNAs encoded by herpes-
viruses target pathways involved in innate immune recognition.
EBV’s miRNAs have been studied by several groups with 
established, EBV-infected cell lines obtained from biopsies of 
nasopharyngeal carcinoma and Burkitt’s lymphoma, or lym-
phoblastoid cell lines (LCLs) derived from infecting primary 
B lymphocytes with EBV in vitro (Dölken et al., 2010; Gott-
wein et al., 2011; Kuzembayeva et al., 2012; Riley et al., 2012; 
Erhard et al., 2013). High-throughput target screens using im-
munoprecipitation of the RNA-induced silencing complex 
(RISC) and deep sequencing have identified many potential 
targets of EBV miRNAs, but the catalogs of predicted targets 
assembled by different groups have a surprisingly small overlap 
(Klinke et al., 2014). This lack of consensus may be due to the 
accumulation of profound differences in gene expression be-
tween different long-term, cultivated EBV-infected cell lines 
that do not reflect the impact of EBV’s miRNAs in vivo.
To circumvent these problems, we developed an ex-
perimental approach using primary human B lymphocytes, 
and analyzed them during their initial days of EBV infection 
(Seto et al., 2010; Vereide et al., 2014). We infected the B lym-
phocytes with two EBV strains with and without miRNA 
genes, compared the gene expression in the infected cells, and 
examined them for their immune recognition.
We found that EBV-encoded miRNAs regulated sev-
eral immune pathways, which affected CD4+ T cell differen-
tiation and activation. In addition, key molecules important 
for interactions with CD4+ T cells were down-regulated. 
EBV miRNAs repressed the secretion of IL-12, which re-
sulted in suppression of type 1 helper T cell (Th1) differenti-
ation. Viral miRNAs controlled gene expression of HLA class 
II and three lysosomal enzymes important for proteolysis and 
epitope presentation to CD4+ T cells. Such a wholesale inhi-
bition of adaptive immune responses by multiple miRNAs 
of a single pathogen is unprecedented. Our findings explain 
the abundance of miRNAs in complex persisting viruses, and 
clarify how EBV can escape elimination for the lifetime of its 
host in spite of intense adaptive immune responses.
RES ULTS
EBV miRNAs control immune regulatory pathways
We searched for cellular targets of EBV's miRNAs, using an 
experimental system that closely mimics human infection 
in vivo. Two strains of EBV, a laboratory strain (wt/B95-8) 
that expresses 13 miRNAs, and its derivative (ΔmiR) that 
expresses none (Seto et al., 2010) were used to infect freshly 
isolated B lymphocytes from six donors. We used carefully 
titrated virus stocks and infected the cells with optimal doses 
of both viruses (Steinbrück et al., 2015). No differences in 
the percentage of infected cells were seen when comparing 
cells infected with wt/B95-8 versus ΔmiR EBV. RNAs were 
isolated on day 5 after infection and sequenced (available 
from GEO under accession no. GSE75776; see Materials and 
methods). Genes that were differentially expressed in cells 
infected with wt/B95-8 versus ΔmiR EBV were identified 
with those having an absolute z-score >1.6 (Fig.  1 A and 
Table S1). These genes included the published miRNA tar-
gets LY75/DEC205 (Skalsky et al., 2012) and IPO7 (Dölken 
et al., 2010). Genes that were consistently down-regulated 
in wt/B95-8 EBV-infected cells were grouped according to 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway categories (Fig. 1 B). Down-regulated genes were 
predominant in pathways linked to apoptosis, cell cycle reg-
ulation, and p53 signaling, which were previously proposed 
to be regulated by EBV miRNAs (Seto et al., 2010; Feed-
erle et al., 2011a,b; Vereide et al., 2014). Unexpectedly, EBV's 
miRNAs also regulated a wide array of genes with functions 
in immunity, such as cytokine–cytokine receptor interactions, 
antigen processing, and HLAs and co-stimulatory molecules 
(Fig. 1, B and C; and Table S1). We immunoprecipitated RISC 
(RISC-IP) and found that 14.5% (±2.4% SD) of all miRNAs 
were of viral origin in wt/B95-8 EBV-infected cells, domi-
nated by miRNAs of the BHRF1 gene cluster (Fig. 1 D). No 
appreciable viral miRNA reads were found in cells infected 
with ΔmiR EBV (Fig. 1 D), suggesting that the B lympho-
cytes of six donors were free of EBV field strains. In wt/
B95-8 EBV-infected cells, we detected viral miRNAs as early 
as day 1 after infection, which reached high levels 5 days post 
infection (dpi; Fig. 1 E). In RISC-IP, detection of mRNAs 
was variable among infected B cells of the different donors, a 
phenomenon that was reported earlier using a related model 
of established infection and PAR-CLIP experiments (Skalsky 
et al., 2012; GEO accession no. GSE41437). Therefore, we fo-
cused our analyses on candidate mRNAs that were uniformly 
regulated in all samples (Fig. 1 C), and used RISC-IP results 
to confirm them (Table S1).
EBV miRNAs inhibit secretion of proinflammatory cytokines 
and antigen presentation
We confirmed that EBV's miRNAs regulate cytokines cen-
tral to immune function. Supernatants from B cells infected 
with the two strains of EBV were assayed for the levels of 
IL-6, IL-10, TNF, IL12B (IL-12p40), IL-12 (p35/p40), and 
IL-23 (p19/p40). We added CpG DNA, which stimulates 
TLR9, for the detection of IL-6 secreted from EBV-infected 
cells (Iskra et al., 2010). B cells infected with wt/B95-8 EBV 
secreted less IL-6, TNF, and IL-12p40 than B cells infected 
with ΔmiR EBV. In contrast, release of the anti-inflamma-
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Figure 1. EBV miRNAs affect major pathways of immunity. (A) A heat map of the most strongly regulated genes in wt/B95-8 or ΔmiR EBV–infected 
B cells of six donors (donor Ad1-Ad6) 5 dpi shows differentially expressed gene transcripts with absolute z-scores >1.6. Blue and red indicate down- and 
up-regulated transcripts, respectively, in wt/B95-8 compared with ΔmiR EBV–infected cells. (B) Shown are gene functions according to KEGG pathway cat-
egories with the identified pathways sorted by statistical significance. The sizes of the orange dots indicate −log10 P value scores. For each of the six donors, 
fold change values of differentially expressed transcripts are plotted. As in A, blue and red indicate down- or up-regulation by EBV miRNAs, respectively. 
Enrichment of specific pathways was estimated by a hypergeometric distribution test via the KEGG API Web service. (C) Inhibition of selected transcripts 
associated with adaptive immune responses is shown together with previously reported targets of EBV miRNAs and common housekeeping genes. Blue 
background shadings indicate genes down-regulated by viral miRNAs (Table S1). (D) Levels of indicated EBV miRNAs in B cells infected with wt/B95-8 or 
ΔmiR EBV–infected B cells of six donors (donor Ad1-Ad6) 5 dpi were quantified by RISC-IP-seq. Mean ± SD are shown. (E) Three miRNAs, which represent 
different primary miRNA transcripts in EBV-infected B cells, were quantified with stem-loop qPCR over time. One of two independent experiments is shown.
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tory cytokine IL-10 appeared to be unaffected by viral miR-
NAs (Fig.  2 A) consistent with our transcriptome analysis 
(Fig. 1 C). Secretion of IL-12 (p35/p40 or IL-12p70) and 
IL-23 (p19/p40), both of which contain the IL-12p40 sub-
unit (Szabo et al., 2003), encoded by the IL12B gene, was sig-
nificantly reduced in wt/B95-8 EBV-infected cells compared 
with ΔmiR EBV-infected cells (Fig. 2 A). Viral miRNAs also 
inhibited the secretion of IL-12p40 from PBMCs infected 
with wt/B95-8 EBV (Fig.  2 B). IL-12p40 secretion from 
PBMCs infected with ΔmiR EBV was reduced when B cells 
were removed from the PBMCs, indicating that B cells are 
the main contributors to release of IL-12p40 in PBMCs. Re-
markably, our transcriptome analysis revealed the consistent 
reduction of IL12B mRNA with EBV's miRNAs, reducing 
it by 80% in all six donors' B lymphocytes (Fig. 2 C). Quan-
titative RT-PCR confirmed this finding (Fig. 2 D).
Multiple EBV miRNAs target IL12B and prevent Th1 
differentiation of naive CD4+ T cells
We investigated whether IL12B was a direct target of 
EBV miRNAs. EBV's miR-BART1, miR-BART2, and 
miR-BHRF1-2 repressed the luciferase activity of the IL12B 
reporter (Fig. 3 A). The mutation of predicted binding sites 
of miR-BART1, miR-BART2, or miR-BHRF1-2 abro-
gated their ability to inhibit the IL12B reporter (Fig.  3 A 
and Fig. S1), confirming the direct control of IL12B by these 
miRNAs. We similarly analyzed miR-BART10 and miR-
BART22, which are present in field strains of EBV but not in 
wt/B95-8 EBV. For these miRNAs, mutations of their pre-
dicted target sites only partially relieved inhibition (Fig. 3 A 
and Fig. S1), suggesting the presence of additional binding 
sites in the IL12B transcript. In summary, these experiments 
validated IL12B as a direct target of multiple viral miRNAs.
IL-12 is critical for differentiation of Th1 cells (Szabo et 
al., 2003). Therefore, we co-cultured naive CD4+ T cells with 
autologous EBV-infected B cells (Fig. 3 B). Relative to ΔmiR 
EBV, wt/B95-8 EBV-infected B cells repressed Th1 differenti-
ation (Fig. 3, C and D). An antibody that neutralizes the func-
tions of IL12B, but not an isotype control antibody, suppressed 
Th1 differentiation when T cells were co-cultured with ΔmiR 
EBV-infected cells (Fig. 3 E), indicating that IL-12, secreted 
from EBV-infected and activated B cells, was responsible for 
generation of Th1 cells. Thus, EBV miRNAs suppress the re-
lease of IL-12 from infected cells and thereby interfere with 
formation of Th1 cells, which are important antiviral effectors.
Viral miRNAs directly and indirectly 
control antigen presentation
Having shown that EBV miRNAs interfere with CD4+ 
T cell differentiation, we turned our attention to molecules 
that are involved in recognition of infected cells by specific 
CD4+ T cells. We quantified levels of surface proteins with a 
role in HLA class II antigen presentation (Fig. 4). All three sub-
classes of HLA class II (HLA-DR, HLA-DQ, and HLA-DP) 
tested were reduced in wt/B95-8 relative to ΔmiR EBV- 
infected B cells (Fig. 4, A and B), as were many co-stimulatory 
and adhesion molecules 5 and 15 dpi (Fig. 4 C). MHC class I 
molecules were also affected, but to a lesser extent.
Among the many co-receptors and adhesion mole-
cules down-regulated in cells infected with wt/B95-8 EBV 
(Fig. 4 C), we searched for direct targets of EBV miRNAs but 
found only CD40 and FAS in RISC-IPs (Table S1), which 
we could not confirm in subsequent luciferase assays using 
miRNAs encoded by wt/B95-8 EBV. Interestingly, the viral 
latent membrane protein 1 (LMP1) activates the CD40 path-
way, inducing important immune co-receptors (Kieser and 
Sterz, 2015), but several viral BART miRNAs were reported 
to control LMP1 expression (Lo et al., 2007; Riley et al., 2012; 
Verhoeven et al., 2016). We tested these findings in our model 
of newly infected B cells, and found reduced but highly 
variable levels of LMP1 transcripts (Fig.  4 D) and protein 
(Fig. 4 E) in B cells infected with wt/B95-8 EBV compared 
with ΔmiR EBV 5 dpi. We identified miR-BART3 and miR-
BART16 as inhibiting LMP1 in reporter assays (Fig.  4 F). 
miR-BART3 is encoded in wt/B95-8 EBV, whereas miR-
BART16 (Fig. 4 F) is only present in field strains of EBV. We 
also tested miR-BART1 and miR-BART17, which were re-
ported together with miR-BART16 to target LMP1 3′-UTR 
(Lo et al., 2007), but failed to confirm that miR-BART1 and 
miR-BART17 target LMP1 (Fig. 4 F). Collectively, our re-
sults showed that viral miRNAs limit LMP1 gene expression 
and thereby indirectly inhibit surface expression of some im-
mune co-receptors and adhesion molecules.
Viral miRNAs target lysosomal enzymes  
and inhibit antigen processing
According to our transcriptome analysis, genes encoding 
lysosomal enzymes actively involved in MHC class II pep-
tide processing (Blum et al., 2013) were inhibited by EBV 
miRNAs (Fig. 1 C). These included IFI30 (coding for IFN-γ–
regulated thiol reductase GILT), LGMN (coding for asparag-
ine endopeptidase AEP alias legumain), and CTSB (coding 
for the peptidase cathepsin B). Expression of all three genes 
was reduced by EBV miRNAs (Fig. 1 C), which we verified 
by quantitative RT-PCR (Fig.  5 A). We found that EBV’s 
miR-BART1, miR-BART2, and miR-BHRF1-2 could di-
rectly regulate IFI30, LGMN, and CTSB gene expression 
via their 3′-UTRs in luciferase reporter assays (Fig. 5 B and 
Fig. S1). Importantly, the knock-down of these three genes 
(Fig. 5 C) resulted in reduced antigen presentation of exog-
enously loaded protein (Fig.  5 D). Collectively, our results 
show that EBV miRNAs interfere with processes involved in 
MHC class II antigen presentation at multiple levels, includ-
ing lysosomal protein degradation, HLA class II expression, 
and co-stimulatory molecule expression.
EBV miRNAs inhibit recognition of infected B cells  
by EBV-specific CD4+ T cells
Next, we asked whether these multiple levels of regulation ulti-
mately resulted in reduced MHC class II–mediated recognition 
on Decem
ber 16, 2016
Downloaded from
 
Published September 12, 2016
2069JEM Vol. 213, No. 10
of EBV-infected cells by antiviral CD4+ T cells. CD4+ T cells 
from EBV-positive individuals were enriched for EBV-spe-
cific T cells by repeated stimulation with irradiated wt/B95-8 
EBV-infected autologous LCLs. The EBV-specific CD4+ 
T cells were then co-cultured with autologous B cells that had 
been infected with the two EBV strains 5 d earlier (Fig. 6 A, 
top). Release of IFN-γ by EBV-specific CD4+ T cells was sub-
stantial when co-cultured with ΔmiR EBV-infected cells as 
targets, but was consistently reduced when co-cultured with 
wt/B95-8 EBV-infected B cells at all cell ratios tested (Fig. 6 B). 
Activation of EBV-specific CD4+ T cells, measured as IFN-γ 
release, was observed in autologous and partially matched but 
not in HLA-mismatched conditions (Fig. 6 C and Table S2), 
indicating that the activation was HLA class II-restricted.
We also tested an antigen-specific CD4+ T cell clone 
(Fig. 6, A [bottom] and D) directed against the FGQ pep-
tide, an epitope derived from the viral glycoprotein gp350 
(Adhikary et al., 2006). We observed dramatically reduced 
T cell activities with target B cells infected with wt/B95-8 
EBV compared with ΔmiR EBVs 5 dpi (Fig. 6 D). T cell 
activities were much reduced at 15 dpi, but a difference 
between wt/B95-8 and ΔmiR EBV-infected target cells 
remained detectable. Weak recognition on day 15 is in ac-
cordance with gp350 protein being delivered as a compo-
nent of the virion (Adhikary et al., 2006) but not synthesized 
during prelatency or latency (Kalla et al., 2010). Interest-
ingly, expression of cell surface HLA class II levels peaked 
between 4 to 10 dpi (Fig. 6 E) suggesting the importance of 
Figure 2. EBV miRNAs inhibit secretion 
of proinflammatory cytokines. (A) B cells 
infected with wt/B95-8 or ΔmiR EBV for 4, 
11, or 18 d were cultivated for an additional 
4 d to determine levels of selected cytokines 
by ELI SA (n = 3). CpG DNA was added where 
indicated. Paired samples from individual do-
nors are connected by solid lines. P values 
were calculated by a paired two-tailed t test. 
<16, under the detection limit (16 pg/ml); *, P 
< 0.05. (B) PBMCs or PBMCs depleted of B cells 
(n = 3) were infected with either wt/B95-8 or 
ΔmiR EBV, and concentrations of IL-12p40 in 
the supernatants of the infected B cells after 
5 d were determined by ELI SA. (C) Shown 
are scatter plots of transcriptomes of B cells 
from six donors infected with wt/B95-8 or 
ΔmiR EBV for 5 d. Fold changes of transcript 
levels are indicated as blue or red dots, indi-
cating down- and up-regulated transcripts, 
respectively. The individual IL12B transcripts 
are highlighted by red circles and the calcu-
lated fold changes (x-values) are provided. (D) 
Transcript levels of IL12B were measured with 
quantitative RT-PCR in RNA preparations of B 
cells infected with wt/B95-8 or ΔmiR EBV for 
5 d (n = 4). **, P < 0.01.
on Decem
ber 16, 2016
Downloaded from
 
Published September 12, 2016
EBV miRNAs support herpesviral immune evasion | Tagawa et al.2070
viral miRNAs that counteract CD4+ T cell recognition in the 
early days of infection.
EBV-specific CD4+ T cells have cytolytic activity 
(Adhikary et al., 2006). In allogeneic, partially HLA-matched 
conditions, EBV-specific CD4+ T cells consistently showed 
stronger cytolysis of target B cells infected with ΔmiR EBV 
than cells infected wt/B95-8 EBV (Fig. 6 F).
Collectively, we have discovered that EBV miRNAs in-
hibit the recognition and elimination of infected B cells by 
HLA class II–restricted CD4+ T cells. Apparently, EBV uti-
lizes multiple miRNAs to interfere with proinflammatory 
cytokines, antigen processing, and epitope presentation of the 
infected B lymphocyte to evade EBV-specific and antiviral 
CD4+ T cells responses early after infection.
DIS CUS SION
EBV infects its human hosts for their lifetime, residing in 
nonproliferating B cells largely invisible to the host's immune 
response (Thorley-Lawson, 2005). EBV, to be the successful 
pathogen that it is, however, must both establish a latent in-
Figure 3. EBV miRNAs inhibit IL12B directly and prevent Th1 differentiation. (A) HEK293T cells were cotransfected with miRNA expression vectors 
and luciferase reporter plasmids carrying a wild-type or mutated 3′-UTR (Fig. S2) as indicated (n = 3). The luciferase activities were normalized to lysates 
from cells cotransfected with the wild-type 3′-UTR reporter and an empty plasmid. wt, wild-type 3′-UTR; mut, mutated 3′-UTR; ∅, empty plasmid. P-val-
ues were calculated by an unpaired two-tailed Student’s t test. *, P < 0.05; ***, P < 0.001, with respect to the luciferase activity of the wild-type reporter 
cotransfected with empty plasmid. (B) Schematic representation of the steps for experiments shown in C and D. Primary B cells sorted from adenoids or 
PBMCs were infected with either wt/B95-8 or EBV ΔmiR EBV and co-cultured with autologous naive CD4+ T cells, which were stimulated with αCD3/αCD28 
antibody-conjugated beads for 7 d. Th1 differentiation was assessed by intracellular staining of T-bet and IFN-γ after stimulation with PMA/ionomycin for 
5 h. (C and D) Naive CD4+ T cells were cultivated for 7 d with autologous, newly infected B cells and αCD3/αCD28 antibody-conjugated beads at indicated 
ratios (n = 5–6). Proliferating PMA- and ionomycin-restimulated Th1 cells were quantified by intracellular T-bet (C) and IFN-γ (D) staining. (D, left) Repre-
sentative flow cytometry analyses; (right) summary of all experiments. Solid lines indicate paired samples from five to six individual donors. (E) Naive CD4+ 
T cells were cocultivated with wt/B95-8 or ΔmiR-infected B cells at a B/T cell ratio of 1:1 (n = 8) as shown in (B). An anti-IL12B antibody was administered 
at a concentration of 5 µg/ml, and an irrelevant antibody of the same isotype was used as a control. Solid lines indicate paired samples from individual 
donors. *, P < 0.05; **, P < 0.01.
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fection and produce and disseminate progeny virus, all in the 
face of robust innate and adaptive immune responses.
Such responses include EBV-specific CD4+ T cells, 
which have an important role in controlling EBV infection 
and disease. For example, patients with EBV-associated tu-
mors treated with virus-specific T cell preparations showed 
better clinical responses if the preparations contained larger 
fractions of CD4+ T cells (Haque et al., 2007; Icheva et al., 
Figure 4. EBV miRNAs control cell surface levels of HLAs and co-receptors. (A) FACS panels show the expression profiles of three HLA class II gene 
families and HLA class I protein on B cells on 5 dpi. One representative example is shown as a histogram for each condition. (B and C) Cell surface expression 
of HLA molecules (B) and of co-stimulatory and adhesion molecules (C) was measured after immunostaining for proteins inhibited by EBV miRNAs. Ratios 
(wt/B95-8 divided by ΔmiR EBV–infected B cells) are shown as median fluorescence intensity (MFI). Means ± SD of experiments with infected B cells from 
5–10 donors are shown. P-values were calculated by a paired two-tailed Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (D) Viral gene expression 
obtained from the transcriptome data shown in Fig. 1 C was quantified for exons to analyze splicing variants precisely. The y-axis shows natural-log values 
(n = 6) with paired samples from individual donors connected by solid lines. Statistical significance was assessed with the repeated-measurements ANO VA. 
*, adjusted P < 0.01. (E) Cell lysates were prepared from B cells infected with wt/B95-8 or ΔmiR EBV for 5 d and analyzed by Western blotting for expression 
of LMP1 and tubulin. An example (top) and the quantification of all results (bottom) are shown. Protein levels were measured relative to tubulin and LMP1 
levels in ΔmiR EBV-infected cells were set to 100%. Mean ± SD are shown (n = 8). (F) Dual luciferase reporter assays with LMP1 3′-UTR are shown (n = 3). 
P-values were calculated by an unpaired two-tailed Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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2013). CD4+ T cells target a wide repertoire of EBV antigens 
from all phases of latent and lytic infection (Adhikary et al., 
2007; Long et al., 2011). CD4+ T cells with specificity for 
structural EBV proteins play a prominent role: they are a uni-
versal component of the T cell repertoire, rapidly detecting 
EBV-infected B cells and killing them directly (Adhikary et 
al., 2006, 2007). Several EBV proteins expressed during its 
lytic phase can inhibit recognition of EBV-infected cells by 
CD4+ T cells (Ressing et al., 2015). The broad-ranging func-
tions of the host shut-off gene product BGLF5 include re-
duction of HLA class II molecules on the cell surface during 
EBV’s lytic, productive phase (Rowe et al., 2007). The late 
glycoprotein gp42, encoded by BZLF2, was shown to asso-
ciate with HLA class II and to hinder recognition by CD4+ 
T cells sterically (Ressing et al., 2003). Both mechanisms are 
unlikely to be operational in newly infected B lymphocytes, 
because the two viral proteins appear not to be expressed in 
the prelatent phase (Kalla et al., 2010). Viral IL-10, encoded 
by BCLF1, is an immunomodulatory protein expressed early 
in infection, but its effects on B cell elimination by CD4+ 
T cells were limited (Jochum et al., 2012). Two additional viral 
gene products reported to affect CD4+ T cell recognition, 
BDLF3 (Quinn et al., 2015) and BZLF1 (Zuo et al., 2011), 
may act during EBV primary infection, because BDLF3 is 
in the virus particle (Johannsen et al., 2004) and BZLF1 has 
been found to be expressed early during infection (Wen et 
al., 2007; Kalla et al., 2010). BDLF3 transcripts were present 
at very low levels, only, whereas BZLF1 transcripts were not 
mapped in our RNA-Seq analysis. Thus, how EBV infection 
escapes detection and elimination by EBV-specific T cells 
during the early phase of infection has remained uncertain.
Here, we present an answer to this question and show 
that EBV uses its large repertoire of miRNAs to target CD4+ 
T cell differentiation and recognition of infected cells. It ap-
pears that EBV’s immunoevasive strategy uses miRNAs, 
which are themselves nonimmunogenic (Boss and Renne, 
2011), rather than viral proteins which themselves would 
be antigenic. EBV induces a state of reduced immunoge-
nicity in infected and recently activated B cells with viral 
miRNAs, which allows the virus to express its latency-associ-
ated antigens avoiding the recognition and elimination by CD4+ 
T cells. Because activated B cells are professional antigen-pre-
Figure 5. Viral miRNAs inhibit two lyso-
somal endopeptidases and a thiol reduc-
tase needed for antigen presentation. (A) 
Transcript levels of IFI30, LGMN, and CTSB 
encoding GILT, AEP, and CTSB, respectively, 
were measured with quantitative RT-PCR (n = 
3). P-values were calculated by a paired two-
tailed Student’s t test. *, P < 0.05. (B) HEK293T 
cells were cotransfected with different miRNA 
expression vectors and luciferase reporter 
plasmids carrying 3′-UTRs as indicated (n = 
3). The luciferase activities were normalized to 
lysates from cells cotransfected with the wild-
type 3′-UTR reporter and an empty plasmid. 
wt, wild-type 3′-UTR; mut, mutated 3′-UTR; 
∅, empty plasmid. P-values were calculated by 
an unpaired two-tailed Student’s t test. *, P < 
0.05; ***, P <0.001, with respect to the lucifer-
ase activity of the wild-type reporter cotrans-
fected with an empty expression plasmid. (C) 
Transcript levels after RNAi knock-down of 
lysosomal enzyme-encoding genes were in-
vestigated. DG-75 cells were transduced with 
commercial siRNAs directed against GAP DH, 
IFI30, LGMN, or CTSB as indicated and tran-
script levels were quantified with RT-PCR. 
Means of three technical replicates are shown. 
(D) DG-75 cell transduced with siRNAs di-
rected against three lysosomal enzymes as in 
(C) were loaded with purified influenza M1 
protein and co-cultured with M1-specific 
CD4+ T cells (epitope LENL; HLA-DRB1*1301-
restricted) for 1 d. After another 16 h, IFN-γ 
secretion was assessed by ELI SA. One of two 
independent experiments is shown as means 
of three technical replicates. 
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Figure 6. EBV miRNAs inhibit recognition and killing of infected B cells by EBV-specific CD4+ T cells. (A) Overview of the co-culture experiments 
used in B–F. Primary B cells sorted from adenoids or PBMCs were infected with either wt/B95-8 or ΔmiR EBV and co-cultured with polyclonal (top) or 
monoclonal (bottom) EBV-specific CD4+ T cells. Polyclonal antiviral CD4+ T cells were selected through stimulation (once in every two weeks) with irradiated 
LCLs infected with wt/B95-8 EBV. (B) Polyclonal EBV-specific CD4+ T cells were co-cultured for 16 h with autologous B cells that had been infected 5 d ear-
lier. Levels of secreted IFN-γ were quantified by ELI SA (n = 3). Several B/T cell ratios were used as indicated. Means ± SD are shown. (C) Autologous, partially 
HLA-matched, or mismatched (mis.) B cells infected with wt/B95-8 or ΔmiR EBV (n = 3; Table S2) were cocultivated with polyclonal EBV-specific CD4+ T 
cells and secreted IFN-γ was quantified by ELI SA after 16 h. The B/T cell ratio was 1:1. Matched HLA class II alleles are indicated. Means ± SD are shown. 
<16 is under the detection limit (16 pg/ml); ∅, only T cells; n.a., not applicable. (D) The gp350-specific CD4+ T cell clone, epitope FGQ (HLA-DRB1*1301), was 
used as effector cells together with autologous B cells from donor JM (Table S2) as targets. B cells had been infected for 15 d with the two EBV strains as 
indicated and were used at an B/T cell ratio of 1:1. After 16 h of co-culture, levels of secreted IFN-γ and GM-CSF were quantified by ELI SA. Means ± SD are 
shown. (E) MFIs measured in flow cytometry analysis of cell surface HLA-DR in primary B cells infected with wt/B95-8 EBV from two different donors were 
calculated. (F) Killing of EBV-infected B cells by EBV-specific CD4+ T cells was analyzed at various B/T cell ratios by Calcein release assays. A representative 
experiment with partially matched EBV-infected target B cells (left; n = 3) and a summary of all independent experiments with partially matched B cells 
(right) are shown. Paired samples from individual donors are connected by solid lines. Means ± SD are shown. P-values were calculated by a paired two-
tailed Student’s t test. **, P < 0.01; ***, P < 0.001.
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senting cells and express multiple immune-activating molecules 
(Wiesner et al., 2008), the need for EBV to control its host cell is 
more urgent than for other complex viruses that do not rely on 
professional antigen-presenting immune cells for their life-cycle.
In our experiments, recognition of early-stage infected 
B cells by CD4+ T cells was strongly inhibited by multiple 
mechanisms, pointing to the biological importance of the 
immunoevasive functions of viral miRNAs. First, IL12B is 
dramatically repressed in wt/B95-8 EBV-infected B cells 
compared with ΔmiR EBV-infected B cells, leading to the 
down-regulation of three IL-12 family cytokines, IL-12B 
(IL-12p40), IL-12 (p35/p40), and IL-23 (p19/p40). At least 
five different viral miRNAs control the fate of the IL12B 
transcript, targeting multiple sites within its 3′-UTR, in-
dicating its critical role in immune regulation by EBV-in-
fected B cells and a redundancy or even cooperativity of viral 
miRNAs. Interestingly, the miRNAs controlling IL12B orig-
inate from different viral transcripts (Barth et al., 2011), sug-
gesting a robust control of IL12B in all phases of EBV’s life 
cycle and in the many cell types EBV infects, which show 
different patterns of miRNA expression (Cai et al., 2006; Qiu 
et al., 2011). Repression of IL12B may not only reduce CD4+ 
T cell differentiation, as shown here, but also regulate T cell 
effector functions (Curtsinger and Mescher, 2010).
Second, lysosomal proteolysis is regulated. Transcripts 
of lysosomal endopeptidases, AEP and CTSB, and a thiol re-
ductase, GILT, which are involved in proteolytic degradation 
and HLA class II epitope generation (Blum et al., 2013), are 
direct targets of the miRNAs miR-BART1, miR-BART2, 
and miR-BHRF1-2. An siRNA-mediated knock-down of 
these three genes in human B cells reduced their recognition 
by clonal epitope-specific CD4+ T cells (Fig. 5, C and D; Mi-
losevic et al., 2005) suggesting an important role of the three 
lysosomal enzymes in antigen processing and presentation via 
MHC class II molecules in human B cells.
Third, HLA class II surface levels are down-regulated 
in B cells infected with wt/B95-8 EBV (Fig. 4 B). We also 
tested if EBV miRNA targeted MHC class II molecules di-
rectly. miRNAs encoded in wt/B95-8 EBV failed to inhibit 
consistently four HLA-DRB1 alleles tested in dual luciferase 
reporter assays and also lacked functional miRNA-binding 
sites. Thus, the reduction of HLA class II molecules is likely 
indirect and may be a consequence of altered lysosomal pro-
cessing of epitopes. Such phenomena might be particularly 
important early during infection when the EBV-activated 
B cells present antigenic peptides of virion components 
(Fig. 6 D) and the expression of HLA class II molecules peaks 
at the cell surface (Fig. 6 E). Together, these findings demon-
strate that EBV miRNAs redundantly and robustly inhibit 
specific immune functions in newly infected B cells that 
may otherwise metabolize viral proteins into HLA class II- 
presented peptides for recognition by antiviral CD4+ T cells.
A limited number of observations have been made 
before on immunomodulatory functions of EBV miRNAs. 
The RNAs encoding the innate immune effector molecules 
MICB (Nachmani et al., 2009) and NLRP3 (Haneklaus et al., 
2012) have been found in cell lines to be inhibited by EBV's 
miRNAs. They were not down-regulated in our experiments 
(Fig. 1 C, Table S1, and GSE75776), which examined their 
levels during early infection of primary B cells. Our studies 
with primary B cells likely avoided the adaptive changes that 
arise during long-term culturing in vitro.
It is not immediately apparent why B lymphocytes release 
proinflammatory cytokines upon infection with EBV. One 
explanation is based on two viral, noncoding RNAs, termed 
EBERs, which are contained in virions and are transcribed in 
all EBV-infected cells. EBERs are known to trigger the endo-
somal TLR3 receptor or the cytosolic RIG-I sensor signaling 
pathway and induce type I interferon and IL-6 synthesis in 
infected B cells (Samanta et al., 2006; Wu et al., 2007; Iwakiri et 
al., 2009), which might lead to the expression of proinflamma-
tory cytokines found in higher concentrations in the superna-
tants of B cells infected with ΔmiR than with wt/B95-8 EBV.
Interestingly, LMP1, a viral membrane protein that is 
predominantly expressed in the latent phase but also early 
upon B cell infection, activates the CD40 pathway, and in-
duces IL-6, adhesion molecules, and important immune 
co-receptors (Kieser and Sterz, 2015). Several viral BART 
miRNAs have been reported to control LMP1 expression 
(Lo et al., 2007; Verhoeven et al., 2016). We confirmed that 
miR-BART16, which is not in the wt/B95-8 EBV strain, 
and miR-BART3, which was not previously known to tar-
get LMP1 directly, do target it (Fig. 4 F). In addition, miR-
BART3 was recently reported to reduce LMP1 protein levels 
in HEK 293T cells (Verhoeven et al., 2016). We failed to 
identify direct targets among the many co-receptors and ad-
hesion molecules down-regulated in cells infected with wt/
B95-8 EBV (Fig. 4 C). It is possible that, on average, BART 
miRNAs repress LMP1 levels in cells infected with wt/B95-8 
EBV, and thereby indirectly inhibit surface expression of some 
immune co-receptors and adhesion molecules, further reduc-
ing immune recognition of EBV-infected B lymphocytes.
EBV induces proliferation of the B cells it initially infects, 
and fosters their survival. We have found that EBV encodes 
miRNAs that regulate multiple facets of a host's adaptive im-
mune response in newly infected B cells. EBV-infected B cells 
lacking viral miRNAs are deficient both in regulating these 
responses and in other miRNA-dependent functions, includ-
ing an inhibition of apoptosis (Seto et al., 2010). These latter 
defects have precluded comparisons of B cells newly infected 
with wt/B95-8 or ΔmiR in humanized mouse models. In in-
fection experiments with these mice, we observed defects in 
persistence after infection with ΔmiR EBV compared with 
wt/B95-8 EBV, possibly resulting from a combination of de-
creased survival and enhanced immune control (unpublished 
data; C. Münz, personal communication).
Collectively, our studies of a model that closely mimics 
physiological infection in the early phase show that EBV's 
miRNAs interfere with CD4+ T cell control through mul-
tiple mechanisms. They inhibit the secretion of cytokines, 
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inhibit antigen processing and presentation, inhibit the dif-
ferentiation of CD4+ T cells, and counteract recognition and 
elimination of infected B cells by EBV-specific CD4+ effector 
T cells. The breadth of EBV's use of its miRNAs to inhibit 
adaptive immune responses is unprecedented and contributes 
to its efficient establishment of a lifelong infection.
MAT ERI ALS AND MET HODS
Patient samples
Surgically removed adenoids and PBMCs were obtained 
from anonymous patients and anonymous volunteer blood 
donors, respectively, from Munich, Germany. The use of this 
human material was approved by the local ethics committee 
(Ethikkommission bei der LMU München) in writing.
Separation of human primary cells
Human primary B and T cells were prepared from adenoidal 
mononuclear cells (MNCs) or PBMCs by Ficoll-Hypaque gra-
dient centrifugation with Pancoll (PAN-Biotech). B cells, CD4+ 
T cells, CD8+ T cells, and naive CD4+ T cells were separated from 
adenoidal MNCs or PBMCs using MACS separator (Miltenyi 
Biotec) with CD19 MicroBeads, CD4 MicroBeads, CD8 Mi-
croBeads, and Naive CD4+ T cell Isolation kit II, respectively.
Cell lines and cell culture
Burkitt’s lymphoma cell lines Raji (EBV-positive), DG-75 
(EBV-negative), HEK293-based EBV producer cell lines 
(Seto et al., 2010), infected human primary B cells, and T cells 
were maintained in RPMI-1640 medium (Thermo Fischer 
Scientific). HEK293T cells were maintained in DMEM me-
dium. All media were supplemented with 10% FBS (Thermo 
Fischer Scientific), penicillin (100 U/ml; Thermo Fischer Sci-
entific), and streptomycin (100 mg/ml; Thermo Fischer Sci-
entific). Cells were cultivated at 37°C in a 5% CO2 incubator.
Preparation of infectious EBV stocks and infection 
of human primary B cells
Infectious EBV stocks were prepared as previously described 
(Seto et al., 2010). In brief, EBV producer cell lines for ΔmiR 
(p4027) and wt/B95-8 (p2089) EBV strains were transiently 
transfected with expression plasmids encoding BZLF1 and 
BALF4 to induce EBV’s lytic cycle. We collected supernatants 
3 d after transfection, and debris was cleared by centrifugation 
at 3,000 rpm for 15 min. Virus stocks were titrated on Raji 
cells as previously reported and used at a multiplicity of in-
fection (MOI) of 0.1 Green Raji units (Seto et al., 2010) for 
infecting primary B lymphocytes with an optimal virus dose 
(Steinbrück et al., 2015). For virus infection, primary B cells 
were cultivated with each virus stock for 18 h. After replace-
ment with fresh medium, the infected cells were seeded at an 
initial density of 5 × 105 cells per ml.
RNA-Seq and RISC-IP
At 5 dpi of human primary B cells, we extracted total 
RNAs with TRIzol (Thermo Fischer Scientific) and Di-
rect-Zol RNA MiniPrep kit (Zymo Research) from six dif-
ferent donors (Ad1–Ad6; Fig.  1) for RNA-Seq, according 
to the manufacturers’ protocols. In parallel, we performed 
RISC immunoprecipitation (RISC-IP) as described previ-
ously (Kuzembayeva et al., 2012). In brief, lysed cells were 
incubated with anti-Ago2 antibody (11A9)-conjugated 
Dynabeads (Thermo Fischer Scientific), washed, and copre-
cipitated RNA was extracted. The cDNA libraries were pre-
pared (Vertis Biotechnologie AG). For RNA-Seq, total RNAs 
were depleted of rRNAs by Ribo-Zero rRNA Removal kit 
(Illumina), fragmented by ultrasonication, and subjected to 
first strand synthesis with a randomized primer. For RISC- 
IP, RNAs were poly (A)-tailed, ligated with an RNA adapter 
at 5′-phosphates to facilitate Illumina TruSeq sequencing, and 
subjected to first strand synthesis with an oligo-(dT) primer. 
The cDNAs were PCR-amplified and sequenced with an 
Illumina HiSeq2000 instrument at the University of Wiscon-
sin Biotechnology Center DNA Sequencing Facility.
Analysis of deep sequencing
For RNA-Seq, processing of paired-end reads (poly-A 
tail filtering, N-filtering, and adapter removal) was done 
using FastQC and R2M (RawReadManipulator). Reads 
were mapped to the human genome (hg19 ‘core’ chromo-
some-set) by STAR (Dobin et al., 2013) and feature counts 
per transcript were determined using featureCounts and 
GEN CODE version 19 annotations, together with EBV’s 
annotation (available from GenBank under accession 
no. AJ507799). To screen differentially regulated genes 
by viral miRNAs, we used a simple but efficient scor-
ing algorithm based on donor/replicate-wise fold changes 
ranks. For each gene g and replicate k, we calculate the 
gene-specific rank score as
  r g =  1 __ m  ∑ 
k=1
n
  r gk , 
where n is the number of all replicates, m the number of all 
genes/transcripts, and rgk is the rank of gene g in sample k. To 
select highly differentially expressed genes, we transformed 
the rank score into a z-score and selected all transcripts with 
an absolute z-score >1.6.
For RISC-IP the mapped reads were normalized using 
size factors estimated with the R package DEseq2 and fil-
tered for reads mapped to annotated 3′-UTR regions using 
GEN CODE version19. To identify local quantitative differ-
ences in the read enrichments on 3′-UTRs between wt EBV 
compared with ΔmiR EBV-infected B cells, we calculated a 
donor-wise relative enrichment score. For each genomic po-
sition p, the relative expression esp was calculated as
  e  s p =  
 e tp  _____  e tp +  e cp ×  n pu , 
where etp is the enrichment value of sequenced reads at po-
sition p in wt/B95-8 EBV-infected cells and ecp the local en-
richment value in ΔmiR EBV-infected B cells, respectively. 
on Decem
ber 16, 2016
Downloaded from
 
Published September 12, 2016
EBV miRNAs support herpesviral immune evasion | Tagawa et al.2076
The normalization factor npu = etp/max(eu) was introduced 
to correct for local maxima in the UTR sequence of inter-
est, where max(eu) is the maximum enrichment value in the 
UTR sequence u. Finally, we used a Gaussian filter to mini-
mize local noise. To select 3′-UTRs bound by viral miRNAs, 
we set the threshold as follows: enrichment score >0.6 for a 
stretch of >20 nt in the 3′-UTRs in two or more donors. 
To quantify viral miRNAs incorporated into the RISC in 
infected cells, we mapped reads from the RISC-IP Seq to 
miRNA entries registered in miRBase 21 and calculated frac-
tions of each viral miRNAs out of total miRNA read counts.
KEGG enrichment pathway
Enrichment of specific pathways was estimated by performing 
a hypergeometric distribution test via the KEGG API Web 
Service. All calculations were done using Matlab (Mathworks).
ELI SA
To detect cytokine secretion from infected B cells, 106 cells 
were seeded in 6-well plates at 4 or 11 dpi, cultivated for 
4 d with cyclosporine (1 µg/ml; Novartis). Supernatants 
were harvested and stored at −20°C. ELI SAs for IL-6, IL-10, 
IL12B (IL-12p40), IL-12, IL-23, and TNF were performed 
following the manufacturer’s protocols (Mabtech). For IL-6 
and IL-10, CpG DNA were added as previously described 
(Iskra et al., 2010) to stimulate infected B cells. ELI SA for 
IFN-γ levels was performed following the manufactur-
er’s protocol (Mabtech).
To detect IL-12p40 secretion from PBMCs or PBMCs 
depleted of B cells using the MACS separator and CD19 
MicroBeads (Miltenyi Biotec), the cells were infected with 
either wt/B95-8 or ΔmiR EBV at MOIs of 0.1 Green Raji 
units (Steinbrück et al., 2015). After 5 d of incubation, super-
natants were collected and ELI SA for IL-12p40 levels was 
assessed following the manufacturer’s protocol (Mabtech).
Luciferase reporter assays
The 3′-UTRs of IL12B (Ensembl ENST00000231228), 
IFI30 (Ensembl ENST00000407280), LGMN (Ensembl 
ENST00000334869), CTSB (Ensembl ENST00000353047), 
and LMP1 (available from GenBank under accession no. 
AJ507799) were cloned downstream of Renilla luciferase 
(Rluc) in the expression plasmid psiCHE CK-2 (Promega). 
To construct the viral miRNA expression vectors, we cloned 
TagBFP (Evrogen) under the control of the EF1α promoter 
into pCDH-EF1-MCS (System Biosciences). Single miR-
NAs of interest were cloned downstream of the TagBFP-en-
coding gene. Viral miRNAs were obtained by PCR from the 
p4080 plasmid (Seto et al., 2010). 50 ng of the psiCHE CK-2 
reporter and 150 ng of the pCDH-EF1 miRNA expressor 
plasmid DNAs were cotransfected into 1 × 105 HEK293T 
cells by Metafectene Pro (Biontex). After 24 h of transfection, 
we measured luciferase activities with the Dual-Luciferase 
Assay kit (Promega) and the Orion II Microplate Luminom-
eter (Titertek-Berthold). The activity of Rluc was normal-
ized to the activity of Fluc (Firefly luciferase) encoded in the 
psiCHE CK-2 reporter plasmid. We performed in silico pre-
diction of EBV miRNA-binding sites on 3′-UTRs primarily 
with TargetScan (Garcia et al., 2011) and used RNAhybrid 
(Rehmsmeier et al., 2004) to screen for 6mer binding sites 
(Bartel, 2009). We performed site-directed mutagenesis with 
overlapping oligo DNAs and Phusion polymerase (NEB).
Quantitative RT-PCR
To quantify mRNA levels RNAs were reverse-transcribed 
with SuperScript III Reverse transcription (Thermo Fischer 
Scientific) and quantitative PCR was performed with Light-
Cycler 480 SYBR Green I Mix (Roche) and LightCycler 480 
Instrument II (Roche) according to the manufacturers’ in-
structions. The following primers were used for the detection: 
HPRT1 5′-TGA CCT TGA TTT ATT TTG CAT ACC-3′ and 
5′-CGA GCA AGA CGT TCA GTC CT-3′; HMBS 5′-CTG 
AAA GGG CCT TCC TGAG-3′ and 5′-CAG ACT CCT CCA 
GTC AGG TACA-3′; IL12B 5′-CCC TGA CAT TCT GCG 
TTCA-3′ and 5′-AGG TCT TGT CCG TGA AGA CTC TA-
3′; IFI30 5′-CTG GGT CAC CGT CAA TGG-3′ and 5′-GCT 
TCT TGC CCT GGT ACA AC-3′; LGMN 5′-GGA AAC 
TGA TGA ACA CCA ATGA-3′ and 5′-GGA GAC GAT CTT 
ACG CAC TGA-3′; CTSB 5′-CTG TGG CAG CAT GTG 
TGG-3′ and 5′-TCT TGT CCA GAA GTT CCA AGC-3′.
To quantify miRNA levels, stem-loop qPCRs were 
performed with TaqMan MicroRNA Reverse Transcrip-
tion kit (Thermo Fischer Scientific) and TaqMan Universal 
Master Mix II (Thermo Fischer Scientific) according to the 
manufacturer’s protocols. RNU6B was used for normaliza-
tion. Following TaqMan MicroRNA assays, specific primers 
(Thermo Fischer Scientific) were used for detection: ebv-
miR-BART2: 197238_mat; ebv-miR-BART3: 004578_mat; 
ebv-miR-BHRF1-3 197221_mat; RNU6B: 197238_mat.
Establishment of EBV-specific effector T 
cells and T cell clones
EBV-specific CD4+ T cell clones were established from 
polyclonal T cell lines that were generated by LCLs or 
mini-LCL stimulation of PBMCs, as previously described 
(Adhikary et al., 2007).
Flow cytometry and antibodies
After immunostainings with fluorophore-conjugated an-
tibodies, single-cell suspensions were measured with LSR-
Fortessa or FAC SCanto (BD) flow cytometers and the 
FAC SDiva software (BD). Acquired data were analyzed with 
FlowJo software Ver. 9.8 (FlowJo). The following fluoro-
phore-conjugated antibodies reactive to human antigens were 
used: anti–human IFN-γ APC (4S.B3, IgG1; BioLegend), an-
ti-CD40 PE (5c3, IgG2b; BioLegend), anti–ICOS-L (B7-H2) 
PE (2D3, IgG2b; BioLegend), anti–PD-L1 (B7-H1) APC 
(29E.2A3, IgG2b; BioLegend), anti-CD86 (B7-2) PE (37301, 
IgG1; R&D Systems), anti-CD54 (ICAM-1) APC (HCD54, 
IgG1; BioLegend), anti–HLA-ABC APC (W6/32, IgG2a; 
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BioLegend), anti-CD80 PE-Cy5 (L307.4; BD), anti-FAS 
(CD45) PE (Dx2, IgG1; BioLegend), anti–HLA-DR unla-
beled (L234, IgG2a; BioLegend), anti–HLA-DQ unlabeled 
(SPV-L3, IgG2a ; AbD Serotec), anti–HLA-DP unlabeled 
(B7/21, IgG3; Abcam), anti–mouse F(ab')2 APC (polyclonal, 
IgG; eBioscience), isotype IgG1 PE (MOPC-21; BioLegend), 
isotype IgG2b PE (MPC-11; BioLegend), isotype IgG1 APC 
(MOPC-21; BD), isotype IgG2a APC (MOPC-173; BioLeg-
end), and isotype IgG2b APC (MG2b-57; BioLegend).
Western blotting
We lysed cells with RIPA buffer (50 mM Tris-HCl, pH 8.0, 
150 mM NaCl, 0.1% SDS, 1% NP-40, and 0.5% DOC) and 
boiled the extracts with Laemmli buffer. Proteins were sepa-
rated on SDS-PAGE gels (Carl Roth) and transferred to nitro-
cellulose membranes (GE Healthcare) using Mini-PRO TEAN 
Tetra Cell (Bio-Rad Laboratories). Membranes were blocked 
for 30 min with Roti-Block (Carl Roth), followed by antibody 
incubation. Secondary antibodies conjugated with horseradish 
peroxidase were used (Cell Signaling Technology) and exposed 
to CEA films (Agfa HealthCare). Protein levels were quantified 
with the software ImageJ. The following primary antibodies 
reactive to human proteins were used: anti–human Tubulin 
(B-5-1-2; Santa Cruz Biotechnology, Inc.). The monoclonal 
antibody (1G6-3) reactive to the EBV protein LMP1 was pro-
vided by E. Kremmer (Institute of Molecular Immunology, 
Helmholtz Zentrum München, München, Germany).
RNAi knock-down and recognition by 
M1-specific CD4+ T cells
4 × 105 DG-75 cells were incubated in 1 ml Accell Delivery 
Media (GE Healthcare) and 1 nmol siRNAs directed against 
GAP DH, IFI30, LGMN, CTSB, or combinations thereof for 
48 h. Influenza M1 protein purified as previously described 
(Nimmerjahn et al., 2003) was added to the medium, and the 
cells were further incubated for 24 h and co-cultured with 
M1-specific CD4+ T cell clone E5 for 16 h (Milosevic et al., 
2005). IFN-γ levels were detected with ELI SA.
T cell differentiation and recognition
Th1 differentiation was assessed by co-culture of sorted naive 
CD4+ T cells and infected B cells 5 dpi. 1 × 105 naive CD4+ 
T cells stained with CellTrace Violet (Thermo Fischer Sci-
entific) and 0.5 or 1 × 105 infected B cells were cultured 
in 96-well plates with Dynabeads Human T-Activator CD3/
CD28 (Thermo Fischer Scientific) and cultivated for 7 d. The 
neutralizing antibody against IL12B (C8.6; BioLegend) or the 
corresponding isotype control antibody (MOPC-21; BioLeg-
end) were added for certain experiments at 5 µg/ml. Cells 
were restimulated with PMA and ionomycin (Cell Stimula-
tion Cocktail; eBioscience) for 5 h and treated with Brefeldin 
A and Monensin (BioLegend) for 2.5 h before fixation. Th1 
population was measured by intracellular IFN-γ staining with 
FIX and PERM Cell Fixation and Cell Permeabilization kit 
(Thermo Fischer Scientific) and subsequent flow cytometry 
analysis. The Th1 population was defined as IFN-γ+ T cells 
in the fraction of proliferating T cells identified via CellTrace 
Violet staining. EBV-specific effector T cells’ activities were 
measured with ELI SA and Calcein release assays. For IFN-γ 
detection from T cells, effector and target cells were seeded 
at 5 × 104 cell per ml (1:1 ratio) each and co-cultured for 
16 h in a 96-well plate (V bottom). IFN-γ levels were de-
tected with ELI SA. IFN-γ concentrations <16 pg/ml were 
considered as not detected.
T cell cytotoxicity assays
Primary infected B cells were purified by Ficoll-Hypaque 
gradient centrifugation, and 5 × 105 target cells were la-
beled with calcein at 0.5 µg/ml. After three washing steps 
with PBS, target and effector cells were co-cultured in a 
96-well plate (V bottom) with different ratios in RPMI red 
phenol-free medium to reduce background signals. After 
4 h of co-culture, fluorescence intensity of the released cal-
cein was measured by the Infinite F200 PRO fluorometer 
(Tecan). As controls, spontaneous calcein release of target cells 
cultivated without effector cells and cells lysed with 0.5% 
Triton-X100 were used to define the levels of no and fully 
lysed target cells, respectively.
Statistical analysis
We used Prism 6.0 software (GraphPad) for the statistical 
analysis. A two-tailed ratio Student’s t test was applied un-
less otherwise mentioned.
Online supplemental material
Fig. S1 shows the predicted miRNA-binding sites and 
mutations tested in 3′-UTR reporter assays. Table S1, 
available as an Excel file, lists the gene transcripts controlled 
by viral miRNAs. Table S2 lists the HLA allele information 
of donors used in co-culture experiments. Online 
supplemental material is available at http ://www .jem .org /
cgi /content /full /jem .20160248 /DC1.
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Figure S1. miRNA binding sites and mutations in 3′-UTR reporters. Partial sequences of 3′-UTRs of selected transcripts, which were analyzed in 
Fig. 3 A and Fig. 5 (A and B) are shown together with corresponding miRNAs and mutations within the 3′-UTRs in reporter vectors. Complementarities are 
based on in silico predictions according to the RNAhybrid algorithm and depicted as Watson-Crick (‘|’) or G:U (‘:’). Nonmatching nucleotide residues are 
indicated (X). They result from mutated mRNA target sequences in the reporter plasmids.
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Table S1, available as an Excel file, is a list of gene transcripts down-regulated by EBV miRNAs in infected B cells. Transcript 
IDs (Ensembl Annotation Release 75), corresponding gene symbols, mean of log2 fold changes, and z-scores are shown. In ad-
dition, transcripts are indicated (yes/no) according to the criteria of the RISC-IP enrichment score as defined in 
the Materials and methods.
Table S2. Donor HLA alleles
Donor HLA class I HLA class II
MB n.a. DRB1*0301,*0701
JM n.a. DRB1*0801,*1301; DQB1*0402,*0603; DPB1*0401,*1301
32 A*0201,*0301; B*3501,*1501; C*0102, *0401 DRB1*1501,*0701; DQB1*0602,*0303; DPB1*0401
List of the donors’ HLA alleles (determined by MVZ Martinsried, Germany) whose B and T cells have been used in co-culture experiments in this study. The HLA alleles were identified by 
deep-sequencing. n.a., not available.
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Infection with Epstein–Barr virus (EBV) affects most humans world-
wide and persists life-long in the presence of robust virus-specific T-cell
responses. In both immunocompromised and some immunocompe-
tent people, EBV causes several cancers and lymphoproliferative dis-
eases. EBV transforms B cells in vitro and encodes at least 44microRNAs
(miRNAs), most of which are expressed in EBV-transformed B cells,
but their functions are largely unknown. Recently, we showed that
EBV miRNAs inhibit CD4+ T-cell responses to infected B cells by
targeting IL-12, MHC class II, and lysosomal proteases. Here we in-
vestigatedwhether EBVmiRNAs also counteract surveillance by CD8+
T cells. We have found that EBV miRNAs strongly inhibit recognition
and killing of infected B cells by EBV-specific CD8+ T cells through
multiple mechanisms. EBV miRNAs directly target the peptide trans-
porter subunit TAP2 and reduce levels of the TAP1 subunit, MHC class
I molecules, and EBNA1, a protein expressed in most forms of EBV
latency and a target of EBV-specific CD8+ T cells. Moreover, miRNA-
mediated down-regulation of the cytokine IL-12 decreases the recog-
nition of infected cells by EBV-specific CD8+ T cells. Thus, EBVmiRNAs
use multiple, distinct pathways, allowing the virus to evade surveil-
lance not only by CD4+ but also by antiviral CD8+ T cells.
adaptive immunity | immune evasion | herpesvirus | CD8 T cells |
microRNA
Epstein–Barr virus (EBV) is a ubiquitous herpesvirus that in-fects the majority of the human population worldwide. Al-
though EBV infection persists for life, most carriers remain
asymptomatic due to a stringent control by virus-specific immu-
nity. An important component of this immunity is EBV-specific
CD8+ T cells, which often expand to high numbers in healthy
carriers or after primary infection. Conversely, the absence of
EBV-specific CD8+ T cells predicts the emergence of EBV-
associated disease in patients after stem cell transplantation
or when afflicted with AIDS (1–3). Dangerous EBV-mediated
complications can be reversed or prevented by transfer of EBV-
specific T cells (4, 5), which further confirms the important role
of continuous T-cell control of EBV infection. Among EBV-
specific T cells, CD8+ T cells predominate; about 0.05–1% of all
CD8+ T cells in healthy donors are typically specific for EBV
latent antigens and about twice as many for lytic antigens (6, 7).
EBV predominantly infects B cells and establishes a latent in-
fection before production of progeny virus becomes possible (8).
Four distinct programs of EBV latent infection have been defined
according to their expression profiles of latent viral genes (9–11).
One of these programs, known as latency III or the “growth
program,” is characterized by the expression of a restricted set of
approximately eight viral proteins, which activate B cells and drive
their proliferation, thus increasing the viral reservoir. Latency III
is found in EBV-associated malignancies in immunosuppressed
patients (9) and likely reemerges continuously in healthy carriers
(9, 12), indicating that its control is critical for the health of an
EBV carrier. Only at a later stage of infection (13) can the virus
enter its lytic phase in infected cells to produce progeny virions, a
phase requiring expression of the majority of viral proteins. Some
of these lytic-cycle viral proteins are immunoevasins that interfere
with CD8+ T-cell recognition: the TAP inhibitor BNLF2a (14, 15);
the G protein-coupled receptor BILF1 that associates with MHC
class I/peptide complexes, diverts them from the exocytic pathway
and the cell surface, and induces their lysomal degradation (16,
17); and the protein BGLF5 that reduces MHC I expression and
CD8+ T-cell recognition as a consequence of its generalized host-
shutoff function (18, 19). Recently, BDLF3 was identified as an
additional lytic-cycle protein that targets MHC molecules for
degradation (20). BNLF2a is also expressed early after infection in
the prelatent phase (13 for a recent review) and reduces CD8+
T-cell recognition in the first days of infection but does not impair
T-cell recognition in established latency (21, 22). It is unclear,
though, how latently EBV-infected B cells escape elimination by T
cells, in particular during the latency III program that is charac-
terized by a considerable antigenic load and an activated state
expected to increase the immunogenicity of B cells (23). In latency
III, MHC I, MHC II, and T-cell–coactivating molecules are highly
expressed (24, 25), but nonetheless many epitopes are suboptimally
recognized by CD8+ T cells (26, 27). Therefore, it is likely that
unknown immunoevasive mechanisms operate in these latently
infected B cells.
Significance
Most humans are infected for their lifetime with Epstein–Barr
virus (EBV), which can cause cancer and other EBV-associated
diseases. Infected individuals develop strong immune responses
to this virus, in particular cytotoxic CD8+ T cells, but viral in-
fection is never cleared nor is EBV eliminated from the body. This
suggests that certain viral molecules might prevent effective
elimination of EBV-infected cells by CD8+ T cells. EBV is rich in
genes coding for microRNAs, many with unknown function. We
show that viral microRNAs interfere with recognition and killing
of EBV-infected cells by CD8+ T cells. Multiple mechanisms and
molecules are targeted by microRNAs to achieve this immune
evasion. Therefore, targeting of viral microRNAs may improve
antiviral immunity and therapy.
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A hallmark of EBV is its array of 44 microRNAs (miRNAs)
(28–31), which is the largest number of miRNAs identified in a
human pathogen to date. Many EBV miRNAs have no known
function. A function of viral miRNAs in innate immunity was sug-
gested earlier by findings showing that some regulate the inflamma-
some component NLRP3 (32), the natural killer group 2D (NKG2D)
ligand MICB (33), and the chemokine CXCL11 (34).
Recently, we found that multiple viral miRNAs limit the
control of infected B cells by CD4+ T cells early in EBV infection
(35). Several viral miRNAs reduce secretion of IL-12, expression
of HLA class II molecules, and expression of lysosomal enzymes
important for antigen presentation to CD4+ T cells. EBV
miRNAs also regulate many molecules of potential importance
in HLA class I presentation and CD8+ T-cell recognition (35).
These findings have led us to determine if viral miRNAs inhibit
surveillance of EBV by CD8+ T cells. We have found that viral
miRNAs do prevent virus-specific activation of CD8+ T cells and
killing of infected B cells; we have also delineated the mechanisms
underlying this viral evasion of the immune response.
Results
EBV MiRNAs Support Survival of Infected B Cells in the Presence of
CD8+ T Cells from EBV-Positive Donors. We used in vitro infection
of primary human B cells as a simple but representative model of
EBV infection (Fig. 1A) to evaluate if EBV miRNAs counteract
immune surveillance by EBV-specific CD8+ T cells. B cells (CD19+)
isolated from peripheral blood mononuclear cells (PBMCs) from
EBV-positive donors were infected with two EBV strains: the lab-
oratory strain B95-8 (WT/B95-8), expressing 13 viral miRNAs, and
its derivative ΔmiR, expressing no viral miRNAs (36). Twelve hours
later, autologous CD8+ T cells were added, and the cells were
cocultured for 4 wk (Fig. 1B), when cell viability was tested in MTT
assays. Surviving cells were further analyzed by flow cytometry for
their identification (Fig. S1).
In the absence of T cells, we observed robust proliferation of B
cells infected with ΔmiR or WT/B95-8 EBV (Fig. 1B). In the
presence of T cells, the survival and outgrowth of infected B cells
was decreased. A strong reduction of viable cells was achieved by
fewer CD8+ T cells for cells infected with ΔmiR EBV than cells
infected with WT/B95-8 EBV (Fig. 1B). Flow cytometry analyses
showed that B cells represented the viable cells in most of the
cultures (Fig. S1). These results indicated that EBV miRNAs
protect EBV-infected B lymphocytes from eradication by anti-
viral CD8+ T cells under these conditions.
EBV MiRNAs Inhibit Recognition, Killing, and Expansion of EBV-Specific
CD8+ T Cells. Earlier studies had shown that B-cell survival could
be compromised in cells infected with the ΔmiR EBV devoid
of miRNAs, because some viral miRNAs contribute to EBV-
associated cellular transformation in the early phase of infec-
tion (36–38). To evaluate a possible role of viral miRNAs in
controlling immune functions of EBV-specific CD8+ T cells, we
established polyclonal EBV-specific CD8+ T cells from different
donors. Sorted primary CD8+ T cells were stimulated every 2 wk
with irradiated lymphoblastoid cell lines (LCLs), which had been
established by infecting primary autologous B cells with WT/
B95-8 EBV (Fig. 2A). For T-cell effector assays, EBV-specific
CD8+ T cells established in this way were cocultured with B cells
that had been infected with WT/B95-8 or ΔmiR EBV 15 d ear-
lier. T-cell activation was quantified by measuring IFN-γ con-
centration in the cell culture supernatants after 16 h or by
determining cytolysis of infected cells after 4 h. We observed
significantly reduced IFN-γ secretion in response to cells in-
fected with WT/B95-8 relative to cells infected with ΔmiR EBV,
both in autologous (Fig. 2B and Table S1) and HLA-matched
conditions (Fig. 2C). Importantly, T cells were not activated by
HLA-mismatched infected B cells or in B-cell–free cultures, in-
dicating that the observed activation was HLA-restricted and
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Fig. 1. EBV miRNAs support infected B cells to abrogate CD8+ T-cell responses. (A) Schematic overview of the experimental system. (B) CD19+ B cells were
isolated from PBMCs of three different EBV-positive donors and infected with WT/B95-8 EBV or ΔmiR EBV stocks. Twelve hours later, infected B cells were
extensively washed to remove free virions. In 96-well microtiter plates 32,000 EBV-infected B cells were seeded per well and CD8+ T cells isolated from the
autologous donors were added at different ratios as indicated. After 4 wk, total cell viability was assessed by MTT assay. Outgrowth of B-cell–only conditions
(without T cells) was set to 100%. The results shown are based on the mean of six technical replicates per data point.
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EBV-specific (Fig. 2C). In cytotoxicity assays, we found that the
viral miRNAs inhibited killing of infected B cells by EBV-spe-
cific CD8+ T cells at all B:T cell ratios and at any HLA-matched
conditions tested (Fig. 2D). It did not matter whether EBV-specific
CD8+ T-cell cultures had been generated by expansion with
ΔmiR or WT/B95-8 EBV-infected B cells; in each case, ΔmiR
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Fig. 2. EBV miRNAs inhibit recognition and killing of infected B cells as well as expansion of EBV-specific CD8+ T cells. (A) Schematic overview of the ex-
periments shown in the remaining panels of this figure. Polyclonal EBV-specific CD8+ T cells were obtained by repeated stimulation (every two weeks) with
autologous irradiated WT/B95-8 EBV-infected LCLs. The T-cell activities of the EBV-stimulated CD8+ T cell were subsequently analyzed with target B cells
infected with WT/B95-8 EBV or ΔmiR EBV stocks. (B) Equal numbers of polyclonal EBV-specific CD8+ T cells and autologous B cells infected for 15 d with the
indicated EBV strains were cocultured. After 16 h, IFN-γ released from T cells was measured by ELISA. Results of three to four biological replicates are shown
for each donor. (C) Polyclonal EBV-specific CD8+ T cells were cocultured with HLA-matched or mismatched EBV-infected B cells and tested as in B. Matched
HLA class I alleles are indicated; mis., mismatched; ∅, only T cells; <16, below the threshold of detection (16 pg/mL). HLA allotypes of the donors are listed in
Table S1. Data are shown as mean values. Error bars indicate SD of three replicates. (D) Cytotoxic activities of EBV-specific CD8+ T cells directed against HLA-
matched infected B cells were analyzed at various B:T cells ratios in calcein release assays after 4 h of coculture as shown in A. A representative experiment
with mean values and SD of four replicates (Left) and the overview of seven donors (Right) are shown. (E) CD8+ T cells of donor 115 were repetitively
stimulated for 2 mo with irradiated autologous B cells infected with WT/B95-8 or ΔmiR EBV as indicated. The expanded effector T cells were assayed with
autologous infected B cells as targets in coculture experiments and tested as in B measuring the IFN-γ released by ELISA. Error bars indicate SD of three
biological replicates. (F and G) CD8+ T cells isolated from PBMCs were stimulated on day 0 and 10 with irradiated B cells infected with the indicated EBV
strains. Absolute numbers of T cells were determined by flow cytometry 10 d later (on day 10 and 20). (F) Expansion of total CD3+ CD8+ T cells. (G) Expansion
of EBV epitope-specific CD8+ T cells, stained with HLA/peptide pentamers as indicated. Results from 3 to 10 different donors are shown. The significance of
difference in the T-cell expansion experiments was calculated by Wilcoxon matched-pairs signed rank test. *P < 0.05, **P < 0.01.
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EBV-infected B cells were better recognized than B cells infected
with WT/B95-8 EBV (Fig. 2E).
Because clonal expansion is essential for effective antiviral T-cell
responses, we also investigated the selective expansion of EBV-
specific CD8+ T cells in response to autologous B cells infected
with either WT/B95-8 or ΔmiR EBV (Fig. 2F). From PBMCs of 10
donors, we sorted CD8+ T cells and stimulated them twice on day
0 and day 10 with irradiated autologous B cells, which had been
infected for 15 d with WT/B95-8 or ΔmiR EBV. Total numbers of
CD8+ T cells obtained at days 10 and 20 (after one or two stim-
ulations) were significantly higher after expansion with ΔmiR
EBV-infected cells compared with WT/B95-8 EBV-infected cells
(Fig. 2F). In the same setting, we also analyzed the expansion of
EBV-specific CD8+ T cells that were specific for five different
epitopes from EBV proteins latent membrane protein (LMP)2A,
EBV nuclear antigen (EBNA)1, and EBNA3A (Fig. 2G). We con-
sistently found increased expansion in response to ΔmiR EBV-
infected cells for each of these specificities (Fig. 2G). Together,
our data suggest that viral miRNAs in EBV-infected B cells reduce
clonal expansion of a wide range of antiviral CD8+ effector T cells.
EBV MiRNAs Inhibit MHC Class I Antigen Processing and Presentation
Pathways. We screened cellular transcripts targeted by EBV
miRNAs and likely critical in fending off antiviral CD8+ T cells.
To identify potential targets, we performed high-throughput
screening with primary B lymphocytes infected with the different
EBV strains and a combination of RNA and RNA induced si-
lencing complexes-immunoprecipitation (RISC-IP) sequencing
(35). With this approach, we identified IL12B and three genes
(IFI30, the IFN-γ-regulated thiol reductase GILT; LGMN, the
asparagine endopeptidase AEP alias legumain; and CTSB, the
peptidase cathepsin B) encoding lysosomal enzymes and impor-
tant for CD4+ T-cell differentiation and antigen processing as
direct targets of viral miRNAs (35). Here, we focused on genes
consistently inhibited by EBV miRNAs and known to play a role
in antigen processing and presentation and cytokine–cytokine re-
ceptor interactions or are considered cell adhesion molecules
according to the Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway categories (Table 1). A subset of corresponding
mRNAs was also enriched in our RISC-IP sequencing analysis
(Table 1), indicating that these mRNAs were most likely direct
targets of EBV miRNAs. Interestingly, TAP1 and TAP2 were
significantly down-regulated in RNA-sequencing (RNA-Seq) ex-
periments, and TAP2 was also found enriched in RISC-IP sequenc-
ing (Table 1). The TAP1/TAP2 heterodimer mediates transport of
antigenic peptides into the ER lumen, where they are loaded onto
MHC class I molecules. The presentation of many EBV epitopes
depends on TAP (39), and thus we delineated the mechanisms by
which EBV miRNAs regulate it.
First, we verified the regulation of TAP1/2 expression by viral
miRNAs. Fifteen days post infection expression of TAP1 and
TAP2 was reduced in B cells infected with WT/B95-8 EBV com-
pared with ΔmiR EBV both at the level of transcript (Fig. 3A) and
protein (Fig. 3B). As a control, we verified that IPO7 (Importin-7),
a known target of EBVmiR-BART3 (40), was also down-regulated
(Fig. 3 A and B). Because RISC-IP (Table 1) in combination with
the in silico target algorithm TargetScan (41) predicted that the
3′UTR of TAP2 was directly targeted by EBV miRNAs, we per-
formed dual luciferase reporter assays to test this assumption. We
cotransfected HEK293T cells with a luciferase reporter plasmid
containing the 3′UTR of TAP2 and single expression plasmids,
each of which encoded one viral primary miRNA.
The expression of exogenous miR-BHRF1–3 significantly de-
creased the luciferase activity of the TAP2 reporter (Fig. 3C, Left).
A mutation within the 3′UTR in the seed-matching region abol-
ished this inhibition completely, demonstrating that TAP2 is a di-
rect target of miR-BHRF1–3 (Fig. 3C). Similarly, miR-BART17,
which is expressed in EBV field strains but not in the WT/B95-8
strain, targeted the 3′UTR of the TAP2 directly at one of two
predicted sites (Fig. 3C; predicted seed sequences are provided in
Fig. S2A). In contrast, we did not observe a regulation of the TAP1
3′UTR by any viral miRNA present in WT/B95-8 EBV (Fig. 3D).
This result suggested that TAP1 may not be a direct target of
EBV miRNAs, consistent with our RISC-IP data (Table 1). A
parallel dual luciferase reporter assay performed for IPO7 served
as a positive control together with miR-BART3 in these assays
(Fig. S2B).
Next, we quantified the levels of classical HLA class I (HLA-A,
-B, and -C) cell-surface expression on WT/B95-8 or ΔmiR
EBV-infected B cells during the course of infection. Steady-state
surface levels of HLA class I molecules are a function of TAP
activities, as HLA class I molecules lacking peptides are unsta-
ble. We consistently observed a slight reduction by 10–20% of
overall surface MHC class I molecules in cells infected with WT/
B95-8 relative to ΔmiR EBV during the entire observation pe-
riod (Fig. 3E). By assaying individual HLA class I alleles, we
found that HLA-B*07, B*08, and B*40 allotypes were reduced
by 20–30%, whereas HLA-A*02 levels were not reduced (Fig.
3F). This finding is consistent with the known preference of
HLA-A*02 (but not of the other allotypes investigated here) to
bind highly hydrophobic peptides, some of which reach the ER
independently of TAP (42). Dual luciferase reporter assays were
performed for HLA-B*07 and B*08, but direct targeting by
miRNAs could not be demonstrated (Fig. S2C).
EBV MiRNAs Control Multiple Facets of Viral Immune Evasion. These
results suggested that EBV miRNAs impose allele-specific con-
trols of HLA molecules, namely affecting HLA-B allotypes. We
therefore asked if HLA-B allotype-restricted antigen presentation
is directly controlled by viral miRNAs (Fig. 4). We cocultured
infected B cells and CD8+ T-cell clones specific for the IED or the
FLY epitope, both of which are derived from the viral LMP2
protein (Fig. 4A). Presentation of the B*40:01-restricted IED
epitope is dependent on active TAP transportation (39), whereas
the HLA-A*02:01–restricted epitope FLY is highly hydrophobic
and presented TAP-independently (26). In a time course experiment
Table 1. Selected genes (cytokine–cytokine receptor
interaction, antigen processing and presentation, and cell
adhesion molecules) and their regulation by EBV miRNAs in
RNA-Seq and RISC-IP experiments
Gene symbol Mean of log-twofold change z score RISC-IP
IL12B −2.3108 −2.5002 Yes
CD274 −0.6644 −2.3705 No
CD80 −0.9250 −2.3533 No
ICAM1 −0.6553 −2.3351 No
TAP2 −0.4012 −2.1261 Yes
TNF −0.6389 −2.0936 No
CD40 −0.4912 −2.0739 Yes
CD58 −0.5088 −2.0568 No
RFX5 −0.3576 −1.9605 No
PSME1 −0.3338 −1.9373 No
CTSB −0.4520 −1.9370 Yes
PSME2 −0.4680 −1.9335 No
CD86 −0.4486 −1.8001 No
TAP1 −0.3426 −1.7800 No
ALCAM −0.4300 −1.6637 No
ICAM3 −0.5567 −1.6273 No
ERAP2 −0.2923 −1.6048 No
IPO7 −0.2826 −1.6870 Yes
Genes were identified by mRNA sequencing of WT/B95-8 vs. ΔmiR-
infected B cells, ranked by z score, and where indicated, confirmed by RISC-
IPs as described in Tagawa and coworkers (35). IPO7 served as a positive
control.
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with B cells infected with either WT/B95-8 or ΔmiR EBV, we ob-
served reactivity of the clonal T cells as early as 5–7 d post infection
(Fig. 4 B and C). EBV miRNAs significantly reduced the activation
of the IED-specific T-cell clone (Fig. 4B) as expected from the
down-regulation of the TAP complex and subsequent reduction of
HLA-B molecules. Surprisingly, the activation of the FLY-specific
T-cell clone was also strongly reduced (Fig. 4C) even though FLY is
a TAP-independent peptide and presented via HLA-A*02:01, which
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was not affected by the expression of EBVmiRNAs (Fig. 3F). These
experiments strongly supported the presence of additional immu-
noevasive mechanisms that affect recognition of the FLY epitope.
To address the possibility that LMP2A/B gene expression may be
regulated by EBV miRNAs, we evaluated the gene transcript levels
by quantitative RT-PCR in infected B cells 15 d post infection and
found LMP2A/B unaffected by viral miRNAs (Fig. 4D). In contrast,
LMP1, a known target of EBVmiRNAs (43, 44), was down-regulated
as expected (Fig. 4D). Similarly, LMP2 protein levels did not
depend on viral miRNAs (Fig. 4E), substantiating the conclusion
measure T cell activities
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that EBV miRNAs regulate the activation of LMP2A/B epitope-
specific T-cell clones without affecting the viral source of the
epitopes they recognize.
In contrast to LMP2A, EBNA1 transcripts appeared to be
under the control of viral miRNAs (Fig. 4D) (35), also resulting
in decreased levels of EBNA1 protein 15 d post infection (Fig.
4E). We therefore tested the recognition of the HPV epitope of
EBNA1 presented by the HLA-B*35:01 allele in a time course
experiment (Fig. 4F). After only 1 day post infection, the HPV-
specific T-cell clone was clearly activated but only when challenged
with ΔmiR EBV-infected B cells. Later on, B cells infected with
either virus presented the HPV peptide, but ΔmiR EBV-infected
B cells were preferentially recognized (Fig. 4F). Regulation of TAP
(Fig. 3 A–C); lower surface levels of the presenting HLA-B allele,
which might be down-regulated similar to other HLA-B allotypes
(Fig. 3F); and reduced levels of EBNA1 gene expression (Fig. 4E)
may all have contributed to this result.
The analysis of EBNA1 epitope presentation did not reveal
why TAP-independent LMP2A-derived peptides presented via
HLA-A*0201 were under the control of viral miRNAs (Fig. 4C).
We speculated that other costimulatory molecules or proin-
flammatory cytokines (35) may be responsible for this TAP-
independent immunoevasive function. In particular, IL-12, which
contributes to the activation of effector T-cell functions (45), was
a possible candidate because it is a direct and prominent target
of at least five different EBV miRNAs 5 d post infection (35)
and was also down-regulated at the transcript level 15 d post
infection (Fig. 3A). To address this possibility, we neutralized
IL-12 secreted from EBV-infected B cells with a suitable anti-
body and measured IFN-γ secretion by the FLY-specific T-cell
clone (Fig. 4G). IL-12 neutralization dramatically reduced the
activation of the T cells cocultured with ΔmiR EBV-infected
cells. T-cell activation with WT/B95-8 EBV-infected target cells
was also affected but to a lesser extent. Very similar results were
observed with polyclonal EBV-specific CD8+ T cells cocultured
with HLA-matched infected B cells (Fig. 4H), showing that
miRNA-mediated regulation of IL-12 was globally decreasing
recognition by CD8+ T cells. This effect, which was clearly evi-
dent for EBV-specific CD8+ T cells, was mild with EBV-specific
CD4+ T cells (Fig. S3).
Discussion
In this study, we show that EBV miRNAs inhibit surveillance
of EBV by CD8+ T cells. Viral miRNAs reduce virus-specific
proliferation, cytokine production, and killing of infected cells by
CD8+ T cells with various EBV latent epitope specificities. We
identified several mechanisms for this inhibition. First, miRNAs
target TAP2 directly, down-regulate the entire TAP complex,
and reduce HLA allotypes that preferentially present TAP-
dependent epitopes. Second, miRNAs repress EBNA1, which
limits the level of a protein but is essential during most forms of
EBV latency. Third, miRNAs diminish IL-12 release by infected
B cells, reducing the virus-specific activity of EBV-specific CD8+
T cells. Thus, EBV miRNAs limit surveillance by CD8+ T cells
through multiple mechanisms, likely contributing to the main-
tenance of lifelong infection.
It is an attractive hypothesis (35) that T-cell immunoevasion in
latency would be most economically achieved by miRNAs due to
their nonantigenicity. This hypothesis is now fully substantiated
by our present findings that EBV miRNAs interfere with several
steps of antigen presentation preventing CD8+ T-cell recognition
of latently infected B cells. These results are complementary to
our previous findings documenting that EBV miRNAs regulate
multiple pathways important for differentiation and activation of
antiviral CD4+ T cells in the first days of infection (35). That
study also provided some evidence that CD4+ T-cell recognition
is also regulated later, as the structural protein gp350 could be
detected by CD4+ T cells in cells 15 d post infection but only
when miRNAs were absent (35). The mechanisms of regulation
we identified in that context—that is, regulation of MHC II,
lysosomal enzymes, and IL-12—are likely relevant in latency as
well and may explain why EBNA-specific CD4+ T cells are
generally impaired in recognizing LCLs (46). The present study
focused on established latency, but because we observed a strong
miRNA regulation of EBNA1 recognition by CD8+ T cells al-
ready on days 1, 2, and 3 after infection, the hypothesis that EBV
miRNAs generally suppress CD8+ T-cell recognition already in
the first days of infection during prelatency (13, 22, 47) deserves
closer investigation in the future.
An overview of EBV miRNAs that directly target pathways
involved in CD8+ and/or CD4+ T-cell recognition of infected B
cells is provided in Table 2. As large subsets of viral miRNAs
are expressed in all phases of EBV’s life cycle (48), it appears
plausible that viral miRNAs inhibit these target molecules
globally. For example, miRNAs miR-BART1, miR-BART2, and
miR-BART22, which target IL-12 (35), are all highly expressed
not only in latency III but also in EBV-infected germinal center
B cells (latency II) and memory B cells (latency 0/I) from healthy
donors as well as different types of EBV-associated cancer cells
(34, 48, 49). Therefore, miRNA-mediated reduction of IL-12
could lead to decreased T-cell activation and recognition at
different stages of infection and malignant disease. Among TAP-
regulating miRNAs, miR-BHRF1–3 is predominantly expressed
initially upon infection and in latency III in vitro (36), but miR-
BART17 also shows expression in memory B cells and cancer
cells (48), suggesting that EBV miRNA-mediated TAP regula-
tion could likewise be important in vivo.
Although EBV-specific immunity is likely to operate at different
stages of latency and lytic replication to control viral infection,
the question of interest is whether latency III, in its own right, is
a target of EBV-specific immunosurveillance by T cells. For
immunosuppressed patients, it appears clear that T-cell deficiency
favors appearance of latency III malignancies (3), that adoptive
T-cell therapy can prevent this (4, 5), and that T-cell therapy fails
if the EBV strain in question does not express crucial CD8+ T-cell
epitopes in a latency III protein (50). Regarding infection in im-
munocompetent carriers, there were early arguments against a
T-cell surveillance of latency III (51), but later studies showed
that latency III-associated CD8+ T-cell epitopes are in fact
under a selective pressure that depends on the frequency of
HLA class I allotypes in a population (52, 53). Cumulatively,
these reports suggest that EBV-specific CD8+ T-cell surveil-
lance of latency III is an important aspect of infection control
in vivo.
In this work, we have analyzed expansion of EBV-specific
T cells, cytokine secretion, and cytolysis to study the interference
of EBV miRNAs with CD8+ T-cell functions. We found such
Table 2. Direct targets of EBV miRNAs with immune functions
Function Gene (protein) EBV miRNAs
Antigen processing CTSB (Cathepsin B) BHRF1–2
BART2–5p
LGMN (AEP) BART2–5p
IFI30 (GILT) BART1–5p
BART1–3p
Peptide transport TAP2 (TAP) BHRF1–3
BART17
Cytokines IL12B (IL-12p40)* BHRF1–2
BART1–3p
BART2–5p
BART10-3p
BART22
*Component of IL-12 (p35/p40) and IL-23 (p19/p40).
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interference for T cells specific for five out of five epitopes from
three different antigens (LMP2A/B, EBNA1, and EBNA3A).
Because this collection contained epitopes with different HLA
class I restrictions, derived from different categories of antigen
(nuclear vs. transmembrane proteins) and with different processing
requirements (TAP-dependent or -independent, proteasome-
or immunoproteasome-dependent), our data indicate that the
cumulative functional impact of miRNAs allows latently in-
fected B cells to hide from CD8+ T cells in general. Our
findings with polyclonal CD8+ T cells of complex composition
corroborated our view.
miRNAs mediate their effects through direct binding to their
target transcripts such as TAP2, for example (Fig. 3C). Because
the recognition of TAP-independent epitopes is also inhibited by
miRNAs, other mechanisms must contribute to the reduced pre-
sentation of the TAP-independent LMP2 epitopes CLG (Fig.
2G) and FLY (Fig. 4). Only a minority of all CD8+ T-cell epi-
topes (including those of viral origin) are expected to be TAP-
independent (42), and the importance of TAP is reflected by the
many herpesviruses that have evolved their own TAP-inhibitory
proteins (54, 55). A broad impact of TAP regulation on the im-
munological status in latency is also suggested by our observation
that viral miRNAs do not affect global levels of HLA-A2, which is
capable of presenting highly hydrophobic peptides that are more
likely to be TAP-independent (39, 56), but do reduce levels of the
HLA class I allotypes tested (HLA-B7, B8, and B40). These
and most HLA class I allotypes are less likely to present TAP-
independent epitopes, because they require the presence of polar
or charged anchor residues in the peptide (57, 58).
Another effect of EBV miRNAs, suppression of IL-12, seems to
act globally on the function of antigen-specific T cells. Although
IL-12 was originally identified as a product of EBV-infected LCLs
(59), its role in EBV-specific CD8+ T-cell immunity has remained
obscure. In addition to its well-known function in promoting Th1
differentiation (60), IL-12 was shown in mouse and human studies
to promote CD8+ T-cell functions such as proliferation, cytolysis,
and IFN-γ production (60, 61) through STAT4 signaling, up-
regulating T-bet, and increasing IL-2 sensitivity (62, 63). In our
experiments, blockade of IL-12 fully reverted the effect of the
miRNA deletion for polyclonal EBV-specific CD8+ T cells (Fig. 4
G and H) but unexpectedly had only a minor effect on polyclonal
EBV-specific CD4+ T cells (Fig. S3). The reason for this differ-
ence is not clear yet, but one possibility may be a differential re-
quirement for costimulatory signals (64). However, as we have
shown (35), EBV miRNAs affect CD4+ T-cell responses through
IL-12 regulation already at the level of differentiation from naive
T cells and thus act on both major classes of T cells. Because we
found IL-12 to be the gene product most strongly down-regulated
by EBV miRNAs, control of this cytokine appears to be central to
the maintenance of EBV infection.
Materials and Methods
Patient Samples. PBMCs and surgically removed adenoid biopsies were
obtained from volunteer blood donors and patients from the Department of
Otorhinolaryngology of the Universitätsklinikum der Ludwig-Maximilians-
Universität München, respectively. The local ethics committee (Ethikkom-
mission bei der Ludwig-Maximilians-Universität München) approved the use
of this human material. Informed consent was not required because the
biopsies originated from disposed tissues from anonymous donors who
underwent routine surgery.
Human Primary Cells, Cell Lines, and Cell Culture. Human primary B and T cells
were prepared from adenoidal mononuclear cells (MNCs) or PBMCs as described
(35). The EBV-positive Burkitt’s lymphoma cell line Raji, HEK293-based EBV
producer cell lines, infected human primary B cells, LCLs, and isolated T cells
were cultivated as described in SI Materials and Methods.
Preparation of EBV Stocks and Infection of Human Primary B Cells. Stocks of
recombinant EBV strains were essentially prepared and quantitated as de-
scribed (65). Details can be found in SI Materials and Methods.
In Vitro Model of EBV Infection (B-Cell Outgrowth Assay). B cells (CD19+) were
isolated from PBMCs of EBV-positive donors and infected withWT/B95-8 orΔmiR
EBV strains. After 12 h, the infected B cells were extensively washed to remove
free virions. CD8+ T cells isolated from the same donors were cocultured at B:T
cell ratios ranging from 8:1–1:2 (seeding 32,000 B cells per well). B cells cultivated
without T cells served as control. Cells were refed weekly. After 4 wk, the cultures
were analyzed for viable cells in MTT assays as previously described (22).
Establishment of EBV-Specific Effector T Cells and T-Cell Clones. EBV-specific
CD8+ T-cell clones were established by limiting dilution from polyclonal
T-cell lines that were generated by stimulating PBMCs with LCLs infected
with WT/B95-8 or from specific T cells directly obtained from peripheral
blood cells by peptide stimulation, IFN-γ capture (Miltenyi Biotec), and
magnetic isolation (66, 67). Likewise, EBV-specific CD4+ T cells were gener-
ated by repetitive stimulation of sorted CD4+ T cells with autologous LCLs
infected with WT/B95-8 EBV as described previously (66).
EBV-Specific T-Cell Recognition. EBV-specific effector T-cell activities were
measured with IFN-γ ELISA and calcein release assays. For IFN-γ detection from
T cells, effector and target cells were cocultured at a 1:1 ratio (5 × 104 cell per
well) for 16 h in a 96-well plate (V bottom). IFN-γ levels were detected with
ELISA following the manufacturer’s protocol (Mabtech). IFN-γ concentrations
below 16 pg/mL were regarded negative. Neutralization of IL-12 was per-
formed with an antibody (2.5 μg/mL), which was added directly to the co-
culture and is directed against the p40 subunit of IL-12 (C8.6; BioLegend). An
analogous isotype control antibody (MOPC-21; BioLegend) was used as a
control.
T-Cell Cytotoxicity Assays. EBV-infected B cells were purified by Ficoll-Hypaque
(PAN-Biotech) gradient centrifugation, and 5 × 105 target cells were labeled with
calcein (Invitrogen) at 0.5 μg/mL. After three washing steps with PBS, target and
effector cells were cocultured in V bottom 96-well plates with different ratios in
RPMI without Phenol Red (PAN-Biotech). After 4 h of coculture, fluorescence
intensities in supernatants were measured by the Infinite F200 PRO fluorometer
(Tecan). As controls, spontaneous calcein release of target cells cultivated with-
out effector cells and cells lysed with 0.5% Triton-X100 (Carl Roth) were used to
define the levels of no and fully lysed target cells, respectively.
T-Cell Expansion Assay. CD8+ T cells were isolated from PBMCs of EBV-positive
donors. We stimulated 1 × 106 CD8+ T cells with 1 × 105 autologous irradi-
ated B cells (infected for 15 d) and 20 U/mL IL-2. Cells were restimulated
every 10 d. At 10 and 20 d after the first stimulation, T cells were stained
with unlabeled HLA/peptide pentamers (Proimmune) for 20 min at 37 °C.
Counterstaining was done with CD8 and CD3-specific antibodies and Pro5
fluorotag (Proimmune) on ice for 30 min. T-cell numbers were determined
using calibrated APC-beads as volume standard by flow cytometry (68).
Luciferase Reporter Assays. Details of the reporter plasmids and the technical
aspects of the dual luciferase reporter assays can be found in SI Materials
and Methods.
Quantitative RT-PCR. Isolation of RNAs and their analyses by PCR are described
in SI Materials and Methods.
Western Blotting. Cell lysis and antibodies used to detect viral and cellular
proteins of interest can be found in SI Materials and Methods.
Flow Cytometry and Antibodies. Techniques and antibodies used to detect
various surface molecules are described in detail in SI Materials and Methods.
Statistical Analysis.Weused Prism 6.0 software (GraphPad) for statistical analysis,
and the two-tailed ratio t test was applied unless otherwise mentioned.
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SI Materials and Methods
Cell Lines and Cell Culture. The EBV-positive Burkitt’s lymphoma
cell line Raji, HEK293-based EBV producer cell lines (36), in-
fected human primary B cells, and isolated T cells were main-
tained in RPMI medium 1640 (Life Technologies). HEK293T
cells were maintained in DMEM. All media were supplemented
with 10% (vol/vol) FBS (Life Technologies), penicillin (100 U/mL;
Life Technologies), and streptomycin (100 mg/mL; Life Tech-
nologies). Cells were cultivated at 37 °C in a 5% (vol/vol) CO2
incubator.
Separation of Human Primary Lymphocytes. Human primary B and
T cells were prepared from adenoidal MNCs or PBMCs by Ficoll-
Hypaque gradient centrifugation. B cells and CD8+ T cells were
isolated using MACS separation columns (Miltenyi Biotec) with
CD19 or CD8 MicroBeads, respectively.
Preparation of EBV Stocks. The recombinant EBV genome desig-
nated WT/B95-8 in this study is identical to plasmid 2089, which
contains the complete EBV strain B95-8 genome, the F factor
origin of replication, the chloramphenicol resistance gene, the
gene for the green fluorescent protein (GFP) under the control of
the cytomegalovirus (CMV) promoter, and the hygromycin re-
sistance gene as a selectable marker in eukaryotic cells (69).
Inactivation of all miRNA genes from this construct resulted in
plasmid 4027, also called ΔmirALL or ΔmiR (36). Infectious
virus was produced by lytic induction of producer cell lines stably
carrying these recombinant EBV genomes in episomal form.
To induce EBV’s lytic cycle in the ΔmiR (4027) or WT/B95-8
(2089) HEK 293 producer cell lines, plasmids coding for BZLF1
and BALF4 were transiently transfected. Supernatants were
collected after 3 d. Virus stocks were titrated using Raji cells as
described in detail recently (65). Isolated primary B cells were
infected with the virus stocks at a multiplicity of infection of 0.1
GRU (Green Raji Units, see ref. 65). Eighteen hours later, the
infected B cells were cultivated in fresh medium at an initial
density of 5 × 105 cells per milliliter.
Luciferase Reporter Assays. The 3′UTRs of TAP2 (ENST00000374897),
TAP1 (ENST00000354258), IPO7 (ENST00000379719), and HLA-
B7/B8 (ENST00000412585/ENST00000425848) were cloned down-
stream of Renilla luciferase (Rluc) into the expression plasmid
psiCHECK-2 (Promega). The pCDH vectors expressing single viral
miRNA were used as previously described (35). The psiCHECK-2
reporter and pCDH-EF1-MCS plasmid DNAs (System Biosciences)
with a viral miRNA of interest were cotransfected into HEK293T cells
using Metafectene Pro (Biontex). miR-BHRF1–3 was expressed from
a modified pLSP plasmid vector (70). It was digested with BamHI
and EcoRI and ligated with miR-BHRF1–3 sequences obtained
from p2089 (36). The resulting pLSP-BHRF1–3 plasmid was digested
with SfiI and XbaI, and the Cerulean gene was inserted as a
phenotypic marker. Twenty-four hours after DNA transfection,
we measured luciferase activities with the Dual-Luciferase
Assay Kit (Promega) and the Orion II Microplate Luminometer
(Titertek-Berthold). The activity of Rluc was normalized to the
activity of Firefly luciferase (Fluc) encoded by the psiCHECK-
2 reporter. Site-specific mutagenesis was performed as previously
described (35). We performed in silico prediction of EBV
miRNA binding sites on 3′UTRs with TargetScan (www.targetscan.
org) (41).
Quantitative RT-PCR. RNA was isolated using the Direct-zol RNA
MiniPrep columns (Zymo Research). RNA was treated with
DNase I (Thermo Fisher Scientific) and reverse transcribed with
SuperScript III Reverse Transcriptase (Thermo Fisher Scien-
tific), and quantitative PCR was performed using the LightCycler
480 SYBR Green I Mix (Roche) and the LightCycler 480 In-
strument II (Roche) according to the manufacturer’s instructions.
The following primers were used:
HPRT1 for 5′-tgaccttgatttattttgcatacc-3′ and rev 5′-cgagcaa-
gacgttcagtcct-3′,
HMBS for 5′-ctgaaagggccttcctgag-3′ and rev 5′-cagactcctccagt-
caggtaca-3′,
GUSB for 5′-cgccctgcctatctgtattcattggaggtg-3′ and rev 5′-gat-
gaggaactcttggtgacagcc-3′,
IPO7 for 5′-tcgccattgtattcgagaaa-3′ and rev 5′-gaatgcatgtag-
taagctgtaccc-3′,
IL12B for 5′-ccctgacattctgcgttca-3′ and rev 5′-aggtcttgtccgtgaa-
gactcta-3′,
TAP1 for 5′-agtgccctggatgcaaac-3′ and rev 5′-agaaagaggatgtggt-
cacg-3′,
TAP2 for 5′-tgcgggacagaaacaacgtc-3′ and rev 5′-agcctgtgagcaat-
caccag-3′,
EBNA1 for 5′-aagcatcgtggtcaaggagg-3′ and rev 5′-gcgacc-
caagttccttcgtc-3′,
LMP1 for 5′-aggctaggaagaaggccaaa-3′ and rev 5′-ctgttcatct-
tcgggtgctt-3′.3gtt
LMP2 for 5′-atcgctggtggcagtatttt-3′ and rev 5′-gagtatgccagcga-
caatca-3′.
Western Blotting. We lysed cells with RIPA buffer [50 mM
Tris·HCl (pH 8), 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40,
0.5% DOC] and boiled the extracts with Laemmli buffer. Pro-
teins were separated on 10% (vol/vol) SDS/PAGE gels (Carl
Roth) and transferred to nitrocellulose membranes (GE Health-
care Life Science) using the Mini-PROTEAN Tetra Cell apparatus
(Bio-Rad). Membranes were blocked for 30 min with Roti-Block
(Carl Roth) followed by antibody incubation. Secondary antibodies
conjugated with horseradish peroxidase were used (Cell Signaling)
and exposed to CEA films (Agfa HealthCare). Protein levels were
quantified with the software ImageJ. The following primary anti-
bodies reactive to human proteins were used: anti-human Tubulin
(B-5–1-2; Santa Cruz), anti-human Actin (AC-74; Sigma), anti-
human IPO7 (ab88339; Abcam), anti-human TAP1 (1.28; Acris),
and anti-human TAP2 (2.17, Acris). Elisabeth Kremmer, Helmholtz
Zentrum München, German Research Center for Environmen-
tal Health, Institute of Molecular Immunology, Munich, pro-
vided the antibodies specific for the EBV proteins LMP2, LMP1,
and EBNA1.
Flow Cytometry and Antibodies. Stained cell suspensions were
measured with the LSRFortessa or FACSCanto (BD Biosciences)
flow cytometers and the FACSDiva software (BD Biosciences).
Acquired data were analyzed with FlowJo software Ver. 9.8
(FlowJo). The following human-specific antibodies were used:
anti–HLA-ABC APC (W6/32, IgG2a; BioLegend),
anti–HLA-Bw6 PE (REA143, IgG1; Miltenyi Biotec),
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anti–HLA-A2 PE (BB7.2, IgG2b; BioLegend),
anti–HLA-B7 PE (BB7.2, IgG2b; Santa Cruz),
anti–HLA-B8 unlabeled mAb (8.L.215; USbiological),
anti-mouse IgG PE (poly4053; BioLegend),
isotype IgG1 PE (MOPC-21; BioLegend),
isotype IgG2b PE (MPC-11; BioLegend),
isotype IgG2a APC (MOPC-173; BioLegend),
anti-CD8 Pacific Blue (RPA-T8; BioLegend),
anti-CD8 PerCP/Cy5.5 (RPA-T8; BioLegend),
anti-CD4 PE (RPA-T4; BioLegend),
anti-CD3 APC (HIT3a; BioLegend),
anti-CD3 APC/Cy7 (HIT3a; BioLegend),
anti-CD19 FITC (HIB19; BioLegend),
HLA-A*0201/CLG pentamer (CLGGLLTMV, LMP2; Proim-
mune),
HLA-B*0702/RPP pentamer (RPPIFIRRL, EBNA3A;
Proimmune), and
HLA-B*0801/QAK pentamer (QAKWRLQTL, EBNA3A;
Proimmune).
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Fig. S1. Composition of long-term cocultures of WT/B95-8 or ΔmiR EBV-infected B cells with autologous CD8+ T cells from three different EBV-positive donors.
Coculture experiments of CD19+ B cells infected with WT/B95-8 EBV or ΔmiR EBV stocks and autologous CD8+ T cells were performed as shown in Fig. 1. After
4 wk, the compositions of the outgrowing cells were analyzed by FACS: B cells (CD19+), CD8+ T cells (CD8+/CD3+), CD4+ T cells (CD4+/CD3+), or cells negative for
all of the four markers are indicated.
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Fig. S2. Predicted miRNA target sites, their mutations, and luciferase assays of selected targets. (A) Partial sequences of 3′UTRs of selected transcripts analyzed
in Fig. 3C and in B below are shown with corresponding miRNAs and mutations within the 3′UTRs in the reporter vectors. Complementarities are based on in
silico predictions according to the RNAhybrid algorithm and depicted as Watson–Crick (‘j’) or G:U (‘:’) pairs. Nonmatching nucleotide residues are indicated (X).
(B and C) HEK293T cells were cotransfected with miRNA expression plasmids and luciferase reporter plasmids carrying either a wild-type or mutated 3′UTR of
IPO7 (B) or the 3′UTR of HLA-B*07/B*08 (C). The luciferase activities were normalized to lysates from cells cotransfected with the wild-type 3′UTR reporter and
an empty plasmid in place of a miRNA plasmid. Data are shown as mean values and SD of three replicates. Mut, mutated 3′UTR; WT, wild-type 3′UTR; ∅, empty
plasmid.
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Fig. S3. IL-12 neutralization barely reduces the activation of EBV-specific CD4+ T cells. Equal numbers of infected B cells (5 dpi) were cocultured with poly-
clonal EBV-specific CD4+ T cells together with an anti–IL-12B antibody or a control antibody of the same isotype (2.5 μg/mL). After 16 h, IFN-γ release was
measured by ELISA. One representative experiment out of four with different donors is shown.
Albanese et al. www.pnas.org/cgi/content/short/1605884113 3 of 4
Table S1. HLA class I types of the donors
Donor HLA-A HLA-B HLA-C
32 *0201, *0301 *3501, *1501 *0102, *0401
59 *11, *24 *35, *40 n.a.
115 *02, *23 *49, *40 n.a.
Albanese et al. www.pnas.org/cgi/content/short/1605884113 4 of 4
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DISCUSSION 
1. In vitro model of EBV infection 
Prior to establishing a stable, latent phase, many viral lytic genes are expressed for 
a short period of time in newly infected B cells during the pre-latent phase, which lasts 
seven to ten days (Kalla and Hammerschmidt, 2012). Among these lytic genes, at least 
two immunoevasins of the lytic cycle, BNLF2a and BCRF1 (viral IL-10), are also 
expressed immediately upon B-cell infection (Jochum et al., 2012a). BNLF2a and viral 
IL-10 interfere with the recognition of infected cells by EBV-specific effector T cells 
and natural killer cells, respectively, but the two gene products are insufficient to 
abolish T cell recognition completely (Jochum et al., 2012a).  
The lack of miRNAs after infection and within the pre-latent phase leads the 
infected B cells to be highly activated, thus presenting a plethora of viral epitopes from 
latent and lytic gene products. Thus, the cells are perfect targets of immune cells and 
presumably rapidly recognized and killed by them (Fig. 1A). Therefore, we decided to 
use an in vitro model of infection to characterize the role of miRNAs in immune evasion 
within the first two weeks after infection.  
 
1.1  Screening and validation of direct targets of viral miRNAs 
Prior to our study, many putative targets of EBV’s miRNAs were identified, but 
only few were experimentally confirmed to be direct targets of EBV’s miRNAs. 
Several groups performed high-throughput screenings, mainly based on RISC-IP, to 
identify direct targets of EBV’s miRNAs. These approaches generated catalogues of 
putative targets but the lists of genes published by several groups show only a small 
overlap (Klinke et al., 2014). The authors used different established EBV-positive B 
cell lines, which often were not related to appropriate negative controls, like 
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corresponding cell lines infected with EBV mutants lacking the miRNAs. Moreover, 
because these cell lines have been culture for many years, they could have accumulated 
several mutations and have undergone clonal selection for in vitro survival that might 
include additional biases.   
For our approach, we wished to steer away from such problems. Consequently, we 
infected primary human B lymphocytes with wt/B95.8 or ΔmiR viruses and performed 
high-throughput screening five days after infection. This model allowed us to directly 
compare B cells infected with wt/B95.8 or ΔmiR virus, which differ with respect to 
their miRNAs coding capacity, only (Seto et al., 2010). We performed both RNA-seq 
and RISC-IP-seq experiments and combined the obtained data to reduce false positive 
candidates. The comparison of RNA-seq data between wt/B95.8 and ΔmiR EBV-
infected cells provided us with a list of candidate genes that were consistently 
downregulated in the presence of viral miRNAs in B cells of six donors tested 
(Publication 2 Fig. 1). The RISC-IP-seq experiments revealed mRNA targets that were 
enriched in the presence of EBV’s miRNAs. Combining the results of the two high-
throughput screening approaches, we generated a list of genes that were both 
downregulated in RNA-seq and enriched in RISC-IP-seq (Publication 1 Supplementary 
Table 1). These genes were considered to be directly targeted by one or multiple viral 
miRNAs. We are aware that this approach has its limitations. The majority of the 
miRNAs interactions cause a downregulation of the target mRNA (Guo et al., 2010), 
but a small fraction of miRNAs rather blocks translation of the target mRNA than 
promoting its degradation. As a consequence, our approach will not identify these 
targets.  
Because our approach is based on next generation sequencing, we introduced 
additional criteria of target validation: mRNA levels were confirmed by qPCR and 
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protein levels of the candidates were analyzed by either WB, ELISA, or Flow 
cytometry. Furthermore, the functional interaction between target and single miRNAs 
had to be demonstrated in “dual luciferase assays”. Towards this end, we cloned the 
3’UTR of the target transcript downstream of a renilla luciferase gene in a reporter 
plasmid and confirmed that the expression of individual viral miRNA led to the 
downregulation of the luciferase activity. To identify the predicted miRNA binding site 
we used bioinformatics tools such as TargetScan 6 (Garcia et al., 2011). In case a 
3’UTR was identified as potential target, the putative miRNA-binding site was mutated 
to abrogate the miRNA-mRNA interaction. A de-repression of the luciferase activity 
would thus indicate a bona fide miRNA-driven target expression regulation. 
 
2. IL-12 downregulation is important for viral immune evasion 
Our RNA-seq experiments generated a catalogue of downregulated transcripts in 
the presence of viral miRNAs. Performing a KEGG enrichment analysis we checked 
which pathways were predominantly affected by EBV’s miRNAs (Publication 1 Fig. 
1B). As expected, apoptosis, cell cycle, and p53 signaling pathways were found to be 
among the top downregulated pathways, confirming previous reports. Interestingly, the 
top pathways regulated by viral miRNAs included those involved in innate and adaptive 
immune responses (Publication 1 Fig. 1B), strengthening our hypothesis that EBV’s 
miRNAs are acting as immunoevasins. 
IL12B was the most prominent target gene constitutively repressed by EBV’s 
miRNAs among the six donors (Publication 1 Fig. 2C). IL12B, also known as IL-12p40, 
is part of a family of heterodimeric cytokines that encompasses IL-12, IL-23, IL-27, 
and IL-35 (Collison and Vignali, 2008). The subunit p40 is the α-chain that can bind 
two different !	chains	p19 or p35, forming IL-23 or IL-12 respectively. IL-12 is a 
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proinflammatory cytokine produced by dendritic cells, B cells, and macrophages in 
response to pathogens’ infection (Vignali and Kuchroo, 2012). IL-12 promotes the 
differentiation of naive CD4+ T cells to antiviral Th1 cells and supports the production 
of IFN-γ from activated T cells (O’Shea and Paul, 2002). Like IL-12, IL-23 is a 
proinflammatory cytokine mainly produced by macrophages and dendritic cells upon 
CD40 activation (Kastelein et al., 2007). In contrast to IL-12, IL-23 is reported to 
enhance the differentiation to CD4+ Th17 cells in mice (Bettelli et al., 2006), stabilizing 
IL-17 production, but it is not an essential differentiation factor of Th17 cells. 
We could confirm the downregulation of IL-12p40 by EBV’s miRNAs at transcript 
and protein levels (Fig. 2A and B), which leads to the reduction of the functional 
heterodimeric cytokines IL-12 and IL-23 (Publication 1 Fig. 2A). As a consequence, 
when co-cultured with wt/B95.8 EBV-infected cells, naive CD4+ T cells showed a 
reduced Th1 differentiation compared to cells infected with ΔmiR EBV (Publication 1 
Fig. 3). The data indicated that the miRNAs prevent the antiviral response of Th1 cells 
limiting the antiviral activity of T cells. Interestingly, we confirmed that five different 
EBV’s miRNAs directly repressed IL12B 3’UTR at seven different positions (Fig. 2C). 
Two of these viral miRNAs are not expressed in wt/B95.8 EBV-infected cells (Seto et 
al., 2010). Our findings suggest that the downregulation of this mRNA targets is 
extremely important for the virus. To our knowledge, this is the first report of a single 
mRNA targeted by that many viral miRNAs.  
As described in the introduction of this thesis, we generated polyclonal EBV-
specific T cell lines from both CD4+ and CD8+ T cells, which were used as tools to 
quantify the antigen presentation of EBV-infected cells. Polyclonal EBV-specific T 
cells co-cultured with B cells infected with wt/B95.8 EBV always showed a lower 
activation compared to the T cells co-cultured with ΔmiR EBV-infected B cells (CD4+ 
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T cells in Publication 1 Fig. 6 and CD8+ T cells in Publication 2) indicating that 
miRNAs prevent recognition of infected cells (explained below in more details). Since 
IL-12 is also reported to be important for T cells activation (Vignali and Kuchroo, 
2012), we tested the contribution of IL-12 in our co-culture system with polyclonal 
EBV-specific T cells. We found that neutralizing IL-12 with a specific antibody 
drastically reduced the activation of EBV-specific CD8+ T cells when co-cultured with 
ΔmiR EBV-infected B cells to a level similar to wt/B95.8 EBV-infected cells (Fig. 2D). 
This result indicated that IL-12 also plays an important role in CD8+ T cells activation. 
Surprisingly, this was not the case with EBV-specific CD4+ T cells because IL-12 
neutralization did not affect their activation (Fig. 2E). To my knowledge, this finding 
has not been reported previously. It emphasizes the critical role of IL-12 with respect 
to CD4+ Th1 cell differentiation, which is independent of T cell activation upon antigen 
encounter. 
IL-12 downregulation was already proposed to be a possible viral strategy to evade 
the host immune response (Smith et al., 2003). In our study, we corroborated this 
hypothesis identifying IL-12 as a key target for viral immune evasion by EBV’s 
miRNAs, suggesting that probably also other viruses may regulate this cytokine for this 
purpose.  
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Fig. 2. IL-12 downregulation is important for viral immune evasion 
A. IL12B 3’UTR scheme together with EBV’s miRNAs (top). Five different EBV’s miRNAs (in red) 
bind to seven different sites within the IL12B 3’UTR. B. mRNA levels of IL12B were measured by 
quantitative RT-PCR. Total RNA was extracted from B cells infected with wt/B95.8 or ΔmiR EBV for 
5 days (n=4). C. B cells infected with wt/B95.8 or ΔmiR EBV for four or 11 days were cultivated for 
additional four days, when the supernatants were collected to perform ELISA to assess the concentration 
of IL-12p40 (n=3). D. and E. B cells infected with wt/B95.8 or ΔmiR EBV and polyclonal EBV-specific 
CD8+ T cells (D) or CD4+ T cells (E) were co-cultured together with an anti-IL12B antibody or a control 
antibody of the same isotype (2.5 µg/mL). After 16 h, supernatants were collected and the IFN-γ release 
by T cells was measured by ELISA. Results from two different donors are shown. * P<0.05; ** P<0.01. 
A
B
Fig. 1. Schematic representation of the genomic location of EBV miRNAs. The top row shows the EBV genes expressed in cells in stage III latency. The blow-ups sh ow the three miRNA
clusters in greater detail. The deletion within the BamHI A fragment of the EBV genome in the B95.8 strain of EBV is indicated. miR-BART2 runs in antisen se orientation to the 3'UTR of
the BALF5 DNA polymerase. miR-BART5* is not expressed due to a partial deletion in B95.8 (modi fied from Ref. [121] ).
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3. Role of viral miRNAs in antigen presentation 
Specific T cell activation is mediated by interactions of TCRs with the HLA-I or 
HLA-II molecules in case of CD8+ or CD4+ T cells, respectively. Each TCR recognizes 
a specific foreign epitope presented by a specific HLA and activates T cells effector 
functions including production of IFN-γ, perforin, and granzyme (mainly released by 
CD8+ T cells). In the absence of additional activating signals, the activation of the T 
cell via its TCR leads to a non-responsive state called “anergy” in which the T cells 
cannot be activated or stimulated anymore. To become functionally active the T cells 
need to form an immune synapse with the target cells. The immune synapse is a tight 
interaction between effector and target cells mediated by the TCR, which confers the 
specificity, adhesion molecules, which improve the stability of the contact, and 
costimulatory molecules, which enhance the activation of the TCR. Only when the 
costimulatory molecules are activated, the TCR activation increases and leads to 
effective T cells functions (Smith-Garvin et al., 2009). A third signal that enhances the 
T cell activation requires pro-inflammatory cytokines such as type I interferon (IFN) 
and IL-12 as already described above. 
In our study, we found that EBV’s miRNAs impaired or repressed all three signals 
required for a productive activation of T cells. 
 
3.1  Regulation of molecules involved in antigen processing and 
presentation 
HLA expression on an antigen presenting cell is enhanced when the cells are 
activated, resulting in a better presentation of foreign antigens to T cells. Upon EBV 
infection, we found that the infected B cells express high levels of HLA-I on the cell 
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surface within days post infection, which lasted for approximately two weeks but 
declined thereafter (Fig. 3A). In this short period of time, infected B cells are clearly 
susceptible to T cells recognition but they also express certain lytic and latent viral 
genes together with the viral miRNAs. 
We found that HLA-I surface levels were slightly reduced over time in B cells 
infected with wt/B95.8 EBV compared with cells infected with ΔmiR EBV (Fig. 3B). 
Not all HLA class I molecules were equally affected (Publication 2 Fig. 3F), but the 
levels of HLA class II molecules were clearly more repressed in B cells infected 
wt/B95.8 EBV (Publication 1 Fig. 4B). The stability of HLA molecules on the cell 
surface is a function of their interaction with peptides. Each HLA can potentially bind 
several different peptides but some have a better affinity and confer a better stability 
than others (Geironson et al., 2012). Empty HLA molecules are not stable. Limiting the 
processing and loading of peptides onto HLA molecules is a well-known strategy of 
many pathogens to hamper or even avoid T cell activation. For this reason, we 
investigated if EBV’s miRNAs were involved in reducing peptide processing and 
presentation. Searching our list of predicted targets of EBV’s miRNAs (Tagawa et al., 
2016), we found several interesting candidates such as TAP2, involved in the processing 
of HLA-I peptides; the lysosomal endopeptidases cathepsin B (CTSB),  legumain 
(LGMN) and the IFN-γ-inducible lysosomal thiol reductase (IFI30); all suggested to be 
involved in HLA-II peptide processing (Blum et al., 2013). 
We validated the candidates as direct targets of different miRNAs: miR-BART-1 
for IFI30, miR-BART-2 for LGMN and miR-BART-2 and miR-BHRF1-2 for CTSB 
(Publication 1 Fig. 5), and miR-BHRF1-3 for TAP2 (Publication 2 Fig. 3). Using a 
siRNA knock-down approach, we analysed the functions of the three lysosomal 
enzymes and confirmed their role in antigen processing and HLA class II presentation 
Role of viral miRNAs in antigen presentation DISCUSSION 
72 
(Publication 1 Fig. 5C and D). It seems plausible that the reduced surface levels of HLA 
class II (-DR, -DQ, and -DP) observed in B cells infected with wt/B95.8 EBV compared 
with cells infected with ΔmiR EBV (Publication 1 Fig. 4B) can be, in part, explained 
with the reduction of the lysosomal enzymes by viral miRNAs. 
The central role of the TAP complex with respect to peptide transportation has been 
characterized already in depth. The importance of this complex is demonstrated by the 
T2 cell lines, in which the TAP complex is completely lacking. In these cells the MHC-
I surface expression is dramatically reduced (Attaya et al., 1992; Spies and DeMars, 
1991; Franksson et al., 1993) and, as a consequence, CD8+ T cells recognition is 
impaired. Interestingly, studies with these cells revealed that certain peptides can be 
presented via a TAP-independent route. Those peptides are highly hydrophobic and can 
thus enter the ER directly, using a mechanism independent of the TAP complex 
(Oliveira and Van Hall, 2013). Due to its molecular characteristics, the HLA-A*02:01 
molecule is able to bind hydrophobic peptides with high affinity. As a consequence, 
peptides presented by this HLA or others with similar characteristics are hardly affected 
in TAP deficient T2 cell lines (P. Cresswell, 1992; Henderson et al., 1992).  
In our model, we observed that viral miRNAs do not reduce surface levels of HLA-
A*02 (Fig. 3C), but HLA-B*07, B*08 and B*40, which all require peptides with polar 
or charged anchor residues are affected (Publication 2 Fig. 3F), probably because their 
transportation depends on TAP (Sutton et al., 1993). 
Because the TAP complex is a common target of several proteins of different 
viruses and HLA-A*02 is able to present peptides TAP-independently, we speculated 
that HLA-A*02 evolved to bypass the action of viral immunoevasins. To evaluate the 
possibility that epitopes presented by HLA-A*02 are not affected by viral miRNAs, we 
used a T cell clone specific for an epitope derived from the viral protein LMP2 termed 
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FLY, which is known to be TAP-independent (Lautscham et al., 2003). The steady state 
levels of LMP2 were not affected by the viral miRNAs (Publication 2 Fig. 4E and F), 
suggesting that it is a perfect model to assess the immunoevasive functions of viral 
miRNAs since the source of the antigenic peptides is not downregulated. As a control 
in these experiments, we used another T cell clone specific for a TAP-dependent 
epitope, derived from LMP2 (IED, presented by HLA-B*40:01). As expected, the 
activation of T cells specific for the IED epitope was reduced by viral miRNAs (Fig. 
3E), but the presentation of the TAP-independent peptide FLY was also reduced (Fig. 
3D). This result strongly suggested that viral miRNAs can also affect additional 
functions beyond TAP-mediated antigen processing and presentation. We found that 
the downregulation of IL-12 might contribute to the observed differences (Publication 
2 Fig. 4G), suggesting that miRNAs affect several steps involved in T cell activation 
and beyond antigen presentation.  
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Fig. 3. Role of miRNAs in antigen presentation 
A. Median fluorescence intensities (MFIs) of three HLA class I major molecules (ABC) on B cells 
infected with wt/B95.8 EBV from two different donors were measured by flow cytometry overtime. B. 
MFIs ratios (%) of HLA class I (ABC) expression of wt/B95.8 versus ΔmiR EBV-infected B cells are 
shown. C. Cell surface expression of specific HLA class I allotypes 15 days post infection. MFIs ratios 
(%) of wt/B95.8 versus ΔmiR EBV-infected B cells are shown. Data are shown as mean and SD obtained 
from experiments with five to ten different donors. D. and E. The presentation of the LMP2 epitope from 
B cells infected with wt/B95.8 or ΔmiR EBV was analyzed with epitope-specific CD8+ T-cell clones 
overtime. Equal numbers of B and T cells were co-cultured. After 16 h, cell culture supernatants were 
collected and IFN-γ release was measured by ELISA at the indicated time points. T cell clones specific 
for the HLA- A*02:01 restricted epitope FLY (D) or the HLA-B*40:01 restricted epitope IED (E) were 
used. A representative time course experiment with mean and SD of three replicates are shown. * P < 
0.05; ** P < 0.01. 
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3.2  LMP1 downregulation is important for immune evasion 
As mentioned previously, the TCR needs co-receptors to be successfully activated 
to trigger a T cell response. Co-receptors contribute to T cells activation in different 
ways. First, adhesion molecules such as LFA-1 and ICAM-1 on T and APCs, 
respectively, can enhance the interaction between T and target cells. Second, co-
receptors such as CD28 on T cells that binds CD80 and CD86 on APCs can directly 
enhance the activation of the TCR. Third, costimulatory molecules on T cells can bind 
receptors on APCs activating them, this results in the upregulation of HLA and 
costimulatory molecules on APC. For example, CD40L on T cells activates the CD40 
receptor on APCs such as B cells, dendritic cells or monocytes. 
In our study, B cells infected with wt/B95.8 EBV showed a significant reduction of 
many co-receptors on their surface compared with ΔmiR EBV-infected cells 
(Publication 1 Fig. 4C). We scrutinized many co-receptors transcripts for their direct 
regulation by miRNAs, but only CD40 gene expression was downregulated in the 
transcriptome analyses and enriched in the RISC-IP seq experiments. Despite these 
hints, we could not confirm CD40 to be a direct target of viral miRNAs. The 
downregulation of CD40 by viral miRNAs would partially explain why costimulatory 
molecules were similarly affected, because CD40 activation upregulates them (Elgueta 
et al., 2009). 
Interestingly, the viral protein LMP1 mimics an activated CD40 receptor, but LMP1 
does not require a ligand to be active (Kieser and Sterz, 2015). Similar to CD40, LMP1 
induces the expression of co-receptors, adhesion molecules, and cytokines such as IL-
6, for example. 
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Two groups independently reported LMP1 to be the direct target of different BART 
miRNAs (Lo et al., 2007; Verhoeven et al., 2016) and we confirmed the direct 
downregulation by viral miRNAs also in our model early after infection (Publication 1 
Fig. 4D, E and F). LMP1 is important for the survival and proliferation of infected B 
cells, but it also upregulates many molecules that may improve T-cells recognition and 
thus promote killing of EBV-infected B cells. It appears as if EBV’s miRNAs fine tune 
or limit the levels of LMP1 to reduce the immunogenicity of EBV-infected B cells. 
This hypothesis explains the reduced levels of many co-receptors in wt/B95.8 EBV-
infected cells even though EBV’s miRNAs do not target cellular co-receptor directly. 
4. Does a single viral miRNA make a difference?
In our studies with infected B cells, we identified many EBV’s miRNAs to be 
important immunoevasins to escape the immune surveillance and support a latent 
infection. In vitro infection of primary B lymphocytes is a valuable model, but it has its 
limits. We always compared B cells infected with ΔmiR EBV with those infected with 
the wt/B95.8 EBV strain, which express up to 13 unique viral miRNAs. In this 
approach, it is not immediately evident which of the many viral miRNAs act as 
immunoevasin. To address this question, we used DG75 cells, a human EBV-negative 
B cell line. In this cell line, we ectopically expressed single EBV’s miRNAs and used 
the cells as antigen presenting cells to evaluate the ability of individual miRNAs to 
interfere with CD4+ or CD8+ T cells recognition (Fig. 4A). We could confirm that miR-
BART1, miR-BART2, and miR-BHRF1-3 are able to act as immunoevasins. 
Surprisingly, the expression of miR-BHRF1-3, which we reported to target TAP2 
(Albanese et al., 2016) and which we confirmed to reduce CD8+ T cells activation (Fig. 
4B), also caused a reduce recognition of CD4+ T cells (Fig. 4C). This finding suggested 
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that miR-BHRF1-3 can also regulate other, so far unidentified cellular targets. In 
contrast, expression of miR-BHRF1-2 that we reported to regulate CTSB (Tagawa et 
al., 2016), which is involved in HLA class II antigen processing, did not result in a 
reduced activation of antigen specific CD4+ T cells activation (Fig. 4C). This 
observation does not necessarily indicate that this miRNA is not involved in immune 
evasion, but rather suggests that it alone is insufficient to produce a noticeable 
phenotypic effect in this experiment. miR-BART3 showed a repression of CD8+ T cells
activation but, in this experiment with DG75 cells, we could not identify any target 
transcript of this viral miRNA (Fig. 4B).  
We investigate the effects of individual viral miRNAs. Expression of single 
miRNAs is enough to reduce the presentation to HLA class I and II molecules, even if 
this was not true for all of them (Fig. 4).  
This model can also be applied to characterize the cooperative action of two or more 
viral miRNAs to assess the biological consequences and to identify additional targets 
of EBV’s miRNAs. 
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Fig. 4. Does a single miRNA make a difference? 
A. Schematic overview of the experimental procedure. Day 1: DG75 cells were electroporated with a 
single miRNA expressing vector together with a plasmid expressing the protein of interest (EBV-BMLF1 
for CD8+ T cells and Influenza-M1 for CD4+ T cells). Day 2: DG75 cells were co-cultured with a CD8+
T cell clone specific for the HLA-A*02 restricted epitope GLC of EBV-BMLF1 (B) or with a CD4+ T 
cell clone specific for the HLA-DRB1*13 restricted epitope LEN of Influenza-M1 protein (C). Day 3: 
Supernatants were collected and the levels of GM-CSF secreted by the T cells were determined by 
ELISA. The results shown are normalized GM-CSF levels obtained with cells transfected with a control 
plasmid encoding no viral miRNA. Experiments are shown with mean and SD of three replicates.  
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5. Are EBV’s miRNAs important only during the pre-latent
phase? 
In our in vitro model, infection of B cells with EBV leads to latently infected cells, 
which proliferate and express the typical latency III genes program. Due to its 
experimental limitation, we cannot directly characterize the immunoevasive function 
of EBV’s miRNAs in cells that maintain the expression profile of latency II, I or 0. 
Compared with latency III, cells in latency II or I are less immunogenic because they 
express fewer viral genes. However, during latency I the viral protein EBNA1 is 
expressed and presented to immune cells. EBNA1 is essential to maintain the viral 
genome in latently infected cells (Yates et al., 1985; Levitskaya et al., 1997).  
To identify whether viral miRNAs can potentially reduce the recognition of EBNA1 
epitopes, we used a T cell clone specific for the epitope HPV of EBNA1 (Fig. 5A). 
Already at one day post infection, activation of this T cell clone was observed, when 
co-cultured with B cells infected with ΔmiR EBV but not with wt/B95.8 EBV. Starting 
from day 2 and onwards, B cells infected with wt/B95.8 virus showed reduced T cells 
activation compared with B cells infected with ΔmiR EBV, indicating that the viral 
miRNAs limit the presentation of EBNA1 leading to less immunogenic B cells. 
Interestingly, we also observed reduced levels of EBNA1 in the presence of miRNAs 
(Fig. 5B), suggesting that lower protein and thus antigen levels together with the 
repression of TAP2 (Publication 2 Fig. 3), HLA-B (Publication 2 Fig. 3F), 
costimulatory molecules (Publication 1 Fig. 4C), and pro-inflammatory cytokines 
(Publication 1 Fig. 2A) all contribute to the reduced activation of EBNA1-specific T 
cells (Fig. 5A).  
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Collectively, our data demonstrate that EBV’s miRNAs prevent recognition and 
elimination of infected B cells by CD4+ and CD8+ T cells probably in all types of viral 
latency.  
We did not investigate if viral miRNAs also play an immune evasive role during 
EBV’s lytic phase. However, since viral miRNAs are also highly expressed during the 
lytic phase, we can assume that they are active together with many others proteinaceous 
EBV immunoevasins during this phase of EBV’s life cycle. Viral miRNAs likely 
improve the chance of lytically infected cells to release progeny viruses, which spread 
to other cells supporting lifelong EBV infection of the host. 
 
 
Fig. 5. EBV’s miRNAs reduce EBNA1 levels and T cells recognition 
A. The presentation of the EBNA1 epitope (HPV) from B cells infected with wt/B95.8 or ΔmiR EBV 
was analyzed with the HLA-B*35:01 restricted and HPV epitope-specific CD8+ T-cell clone. Equal 
numbers of B and T cells were co-cultured. After 16 h, supernatants were collected and the IFN-γ release 
was measured by ELISA at the indicated time points. A representative time course experiment with mean 
and SD of three replicates are shown. B. Western blot analysis of EBNA1 in B cells infected with 
wt/B95.8 or ΔmiR EBV 15 dpi. Representative example of one out of four different donors is shown.
∆miR 
wt/B95.8
A B
HPV (EBNA1; B*35:01)
days post infection
1 2 3 10 150
100
200
300
400
IF
N
-
 (p
g/
m
l)
Tubulin
EBNA1
∆miR wt/B95.8
 - 80 kDa 
 - 50 kDa 
Circulating microRNAs  DISCUSSION  
  
   81 
 
6. Circulating microRNAs 
In this study, we identified EBV’s miRNAs as viral immunoevasins, a previously 
unknown function. They reduce the immunogenicity of infected B cells and interfere 
with the host’s adaptive immunity. Viral miRNAs affect several nodes of intercellular 
communication: they reduce cell-cell contact between infected cells and immune cells 
by reducing the surface levels of HLAs and costimulatory molecules. Viral miRNAs 
also repress the release of cytokines, in particular the important pro-inflammatory 
cytokines IL-6 and IL-12.   
Viral miRNAs are also secreted in extracellular vesicles, but we have not 
investigated whether the virus also utilize this route of intercellular communication to 
its advantage. 
 
miRNAs has been reported to be present in every body fluid, such as blood, urine, 
and saliva (Gallo et al., 2012; Merchant et al., 2010; Zhou et al., 2012; Lässer et al., 
2011). miRNAs can be potentially released from every cell type via extracellular 
vesicles (EV). Different classes of EVs can be released: exosomes, microvesicles, and 
apoptotic bodies, which were all reported to contain miRNAs (Valadi et al., 2007; 
Zernecke et al., 2009). Apoptotic bodies are heterogeneous vesicles ranging from 50 to 
5000 nm in diameter. They are produced by cells that undergo programmed cell death, 
which ensures the dismantling of the cell without causing a strong immune reaction. 
Apoptotic bodies are recycled by cells with phagocytic activity (Simpson and 
Mathivanan, 2012; Taylor et al., 2008). 
In contrast to apoptotic bodies, exosomes and microvesicles are produced under 
physiological conditions and are smaller in size, but differ with respect to the secretory 
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pathways which release them. Microvesicles, also known as ectosomes, directly shed 
from the plasma membrane, while exosomes are formed by inward budding from large 
multivesicolar bodies (MVB), which then fuse to the plasma membrane and release the 
contained exosomes (Kalra et al., 2016). In our experimental model cells do not 
undergo cell death, thus the term EV refers here to exosomes and microvesicles, only. 
Extracellular vesicles can interact with target cells in various ways: proteins on the 
EV surface can interact with receptors of target cells, EVs can fuse with the plasma 
membrane of their target cells and release the EVs’ content, or, mainly in the case of 
phagocytic cells, EVs can be internalized to endosomes and the content is either 
released to the cytoplasm or passes on to lysosomes where the EVs are degraded (Zhang 
et al., 2015).  
Many groups reported that the profiles of cellular miRNAs expression in cells differ 
from that in EVs, and certain miRNAs appear to be preferentially sorted into EVs, but 
it is not clear how the miRNAs are actively enriched, different routes were proposed 
(Guduric-Fuchs et al., 2012; Ohshima et al., 2010; Squadrito et al., 2014; Kosaka et al., 
2013; Villarroya-Beltri et al., 2013; Koppers-Lalic et al., 2014). 
Interestingly, extracellular miRNAs are not only found in EV, but also in a complex 
with high density lipoproteins (Tabet et al., 2014; Vickers et al., 2011) or bound to 
RNA binding proteins such as Ago2 (Arroyo et al., 2011). Surprisingly, all circulating 
miRNAs seem to be protected from degradation by RNases, which are ubiquitously 
present in all body fluids (Zhang et al., 2015). 
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6.1  Circulating EBV’s miRNAs 
EBV’s miRNAs are also reported to be released by LCLs via extracellular vesicles 
(Canitano et al., 2013; Haneklaus et al., 2012; Pegtel et al., 2010). EVs released by 
lymphoblastoid cell lines (LCLs) deliver EBV’s miRNAs to recipient cells such as 
monocytes, monocytes derived dendritic cells (moDCs) (Pegtel et al., 2010), 
plasmacitoid dendritic cells (pDCs) (Baglio et al., 2016), or epithelial cells. EVs appear 
to be taken up by target cells via a caveola-dependent endocytosis (Nanbo et al., 2013). 
Once taken up by the cells, viral miRNAs could potentially regulate different cellular 
targets. Pegtel et al. suggested that EVs with viral miRNAs are transfered from LCLs 
to moDCs where the released miRNAs repress the expression of known targets of 
EBV’s miRNAs such as CXCL11 and LMP1. The authors transfected a luciferase 
reporter vectors with the 3’UTR of these genes into moDCs and treated the cells with 
EVs released from LCL. In this condition, the luciferase activity was reduced, 
suggesting that EBV’s miRNAs transferred via these EVs can  regulate the 3’UTR of 
the two targets tested in moDCs (Pegtel et al., 2010). Along the same line, Haneklaus 
et. al. showed that EVs released by LCLs are taken up by THP1 cells, a monocytic cell 
line, in which they reduced the expression of the inflammasome component NLRP3 
limiting a possible pro-inflammatory environment (Haneklaus et al., 2012).  
 
6.2  A possible new role of circulating EBV’s miRNAs in recipient 
cells 
Since EBV’s miRNAs are reported to be released by EVs, which are taken up by 
professional antigen presenting cells (APC), it is likely that viral miRNAs act as 
immunoevasins also in recipient cells, similarly to what we already described in EBV-
infected B cells. APCs, in particular DCs, are known to modulate immune responses 
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during infection. DCs are able to capture vesicles from infected B cells including 
apoptotic bodies and cross-present their proteinaceous content to both CD4+ and CD8+ 
T cells. As such, DCs contribute to the immune control of EBV infection and support 
the priming and activation of innate and adaptive immunity against the virus (Bickham 
et al., 2003). 
It is important for the virus to reduce or even suppress viral antigens presentation 
and avoid antiviral responses by APCs in the vicinity of EBV-infected or reactivated 
cells. EBV’s miRNAs released by EVs seem to be a perfect way to achieve this goal.  
To scrutinize this possibility, we characterized the EVs released from infected B 
cells. First, we optimized the protocol of EV purification (Fig. 6A). After sequential 
centrifugation steps, the EV containing fraction is loaded at the bottom of a density 
gradient using Optiprep, a solution of 60% iodixanol in water with a specific density of 
1.32 g/ml to separate EVs from molecular particles with a higher specific weight.  EVs 
float with a density of EVs 1.06 - 1.13 g/ml. We quantified the EVs content of each 
fraction after the density gradient centrifugation using the Nanoparticle Tracking 
analysis (NTA; Fig. 6B) and by Western Blot immune detection (WB; Fig. 6C). NTA 
is a light scatter-based method, which allows the enumeration and sizing of 
submicroscopic particles (Gardiner et al., 2013; Dragovic et al., 2011). After density 
gradient centrifugation using the NTA, we could show that the EVs were enriched in 
fraction two and three (Fig. 6B), which was confirmed by WB (Fig. 6C). The two 
proteins detected were TSG101 and LMP1, a cellular and a viral protein, respectively, 
both of which were reported to be enriched in EVs from EBV (Verweij et al., 2015; 
Baranyai et al., 2015). After validation of the purification method, we continue with the 
further functional characterization of the purified EVs. 
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First, we asked if viral miRNAs are included in the EVs as reported previously. We 
isolated EVs from wt/B95.8 EBV-infected B cells and extracted RNA from each 
density gradient fraction followed by quantitative RT-PCR using primers specific for 
different EBV mature miRNAs (Fig. 6D). We could confirm the presence of all the 
miRNAs tested within the EV fractions two and three. Interestingly, in fraction eight, 
where no EVs were detected, we could detect viral miRNAs (Fig. 6D) indicating that 
they do exist in a EV-free form as already described by Arroyo et al. (Arroyo et al., 
2011). Certain miRNAs appeared to be more enriched in the EVs fraction (miR-
BART1), some appear to be excluded (miR-BART3), and others are equally distributed 
(miR-BHRF1-2 and human miR-16).   
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Fig. 6. Circulating EBV’s miRNAs 
A. Schematic overview of the EVs purification method. EBV-infected cells were seeded at 0.5x106 
cells/ml using complete RPMI supplemented with 2% FCS. FCS has been previously depleted from EVs 
through ultracentrifugation at 100,000g overnight, followed by ultrafiltration using 300 kDa Amicon 
centrifugal filters. After 78 hours, the supernatant was collected and centrifuged at 300g for 10 min 
followed by 2000g for 20 min and filtration through a 0.45 µm filter. The cleared supernatant was then 
ultracentrifugated at 100,000g for 2 hours. The pellet was resuspended in PBS and centrifugated again 
at 160,000g for 1.5 hours. The pellet was resuspended in PBS and loaded at the bottom of an Optiprep 
discontinuous gradient, which was centrifugated at 100,000g for 16 hours. Ten fractions of 400 µl each 
were collected and further characterized. B. Quantification of each Optiprep fraction by NTA. C. WB of 
the Optiprep fraction using antibodies specific for the human protein TSG101, a marker of EVs, and the 
viral protein LMP1. Cell lysates (CL) and protein from lysates of EV preparations prior to gradient were 
used as controls. D. Quantitative RT-PCR of human and viral miRNAs in the Optiprep fractions. Values 
are normalized using the miRNA levels derived from 200ng total RNA prepared from cell lysates.  
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Viral miRNAs within EVs can be potentially active once released and transferred 
to the recipient cells. But which are the target cells that take up EVs released by EBV-
infected cells? 
To address this question, we performed a simple experiment: highly purified EVs 
from EBV-infected cells were stained with the dye PKH26, which stains membranes 
due to its lipophilic tail. PKH26 stained EVs were incubated with isolated PBMCs. 
Cell-types specific markers were used to identify, which cells “interacts” with higher 
affinity to EVs from EBV-infected B cells (Fig. 7). We recapitulated the previously 
described results in different cell types, including DCs, pDCs, and monocytes (Baglio 
et al., 2016; Pegtel et al., 2010; Haneklaus et al., 2012). Interestingly, B cells, the cells 
of origin of the EV, interact with EVs only weakly, while no interaction was observed 
between EVs with T cells (Fig. 7). These finding supported our hypothesis that EVs are 
taken up by APCs and that they can potentially act as immunoevasins also inside the 
recipient cells.  
It is important to note that the “interaction” of EVs with recipient cells observed in 
these experiments does not indicate that the content of EVs is taken up and released 
into the target cells. Further experiments are needed to unequivocally prove the release 
of the EVs’ cargo into target cells and the functionality of the transferred miRNAs to 
understand the role of viral miRNAs inside the recipient cells. 
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Fig. 7. Identification of target cells of EVs released by EBV-infected cells 
EVs stained with the PKH26 dye were incubated with isolated PBMCs for 4 hours (using a ratio 1:1000 
cells: EVs). After 4 hours, cells were extensively washed and stained with antibodies specific for cellular 
markers of interest. Stained cells were analyzed by flow cytometry for the PKH26 signal in the PE gate. 
One representative experiment of two is shown. 
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7. Conclusive Remarks 
Our data show that the expression of viral miRNAs has a tremendous consequence 
on the biology of EBV-infected cell. We demonstrated that EBV’s miRNAs are 
essential for the virus to establish its latent phase and for the infected cells to survive. 
Viral miRNAs promote the cell cycle of infected cells, repress apoptosis and drastically 
reduce the immunogenicity of the infected cells. The impact of EBV’s miRNAs is 
unconventionally strong and global, since miRNAs usually only fine-tune the 
expression of their target genes. EBV expresses 44 different miRNAs and our 
contribution to the field showed that many co-act on the same mRNA transcript causing 
a considerable reduction of the target expression levels. The downregulation of IL-12 
exemplifies this concept the best.  
This is the first report uncovering that miRNAs of viral origin play such a key 
functional role for the virus, but it is likely that other viruses use similar mechanisms. 
This finding will pave the way for future studies in this direction. Understanding the 
biology of viruses will facilitate to find ways of fighting pathogen-associated diseases.  
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ABBREVIATIONS 
 
AGO   argonaute 
APC   antigen presenting cell 
BART  Bam HI-A region rightward transcript 
BCR   B cell receptor 
BHRF1  Bam HI fragment H rightward open reading frame 1 
BHV   bovine herpes virus 
BL   Burkitt’s lymphoma 
CD   cluster of differentiation 
CTL   cytotoxic T cell 
CPX   cowpox virus 
CR   complement Receptor 
CTSB  cathepsin B 
DC   dendritic cell 
DNA   deoxyribonucleic acid  
EA-D   EBV early antigen 
EBER   Epstein–Barr virus-encoded small RNAs  
EBNA  Epstein Barr Nuclear Antigen 
EBV   Epstein Barr virus 
EHV   equine herpes virus 
ELISA  enzyme-linked immunosorbent assay 
IFN   interferon 
ERAP1  endoplasmatic reticulum aminopeptidase 1 
EV   extracellular vesicles 
FCS   fetal calf serum 
GM-CSF  granulocyte-macrophage colony stimulating factor  
GP   glycoprotein 
HCMV  human cytomegalovirus 
HHV-4  human herpesvirus 4  
HL   Hodgkin lymphoma 
HLA   human leukocyte antigen 
HSV   herpes simplex virus 
ICAM   intercellular adhesion molecule 1 
IFI30   interferon, gamma-inducible protein 30 
Ig   immunoglobulin 
IL   interleukin 
IM   infectious mononucleosis 
IP   immunoprecipitation 
KHSV  Kaposi's sarcoma-associated herpesvirus  
KO   knockout 
LCL   lymphoblastoid cell line 
LFA  lymphocyte function-associated antigen  
LGMN  legumain 
LMP   latent membrane protein 
MFI   median fluorescent intensity 
MHC   major histocompatibility complex  
MIC   MHC class I polypeptide-related sequence  
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miR/miRNA microRNA 
MO   monocyte 
moDC  monocytes derived DC 
MOI   multiplicity of infection 
MTT   [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]  
MVB   multivescicular bodies 
NK   natural killer 
NKG2D  natural killer group 2D 
NTA   nanoparticles tracking analysis 
OD   optical density 
PCR   polymerase chain reaction 
ORF   open reading frame 
PBMC  peripheral blood mononuclear cell 
PBS   phosphate-buffered saline 
pDC   plasmacytoid DC 
PE   phycoerythrin 
PTLD   post-transplant lymphoproliferative disease 
qPCR   quantitative PCR 
RISC   RNA-induced silencing complex 
RNA   ribonucleic acid 
KEGG  Kyoto Encyclopedia of Genes and Genomes 
RPMI   Roswell park memorial institute 
RT-PCR  real time PCR 
WB  western blot 
SD   standard deviation 
Seq   sequencing 
snoRNA  small nuclear RNA 
SV40   simian virus 40 
TAP   transporter associated with antigen processing  
TCR   T cell receptor 
Th   T helper cells 
UTR  untranslated region 
VCA   viral capsid antigen 
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